99th Annual Meeting“Clinical Trial Advancement throughMultidisciplinary Integration of Immunotherapy”

AMERICAN RADIUM SOCIETY

Final Program

May 6-9, 2017The Broadmoor, Colorado Springs, CO

President: Quynh-Thu Le, MDProgram Chair: Joseph Herman, MD, MSc

Message from the President

American Radium Society (ARS) 11300 W. Olympic Blvd., Suite 600 Los Angeles, CA 90064P: (310) 437- 0581x128F: (310) 437- 0585 E: info@americanradiumsociety.org

ARS is managed by BSC Management , Inc. 11300 W. Olympic Blvd., Suite 600 Los Angeles, CA 90064P: 310- 437- 0555, Ext . 101F: 310- 437- 0585 E: info@bscmanage.com www.bscmanage.com

The Mission of The Society is to promote the multi-disciplinary and collegial study of all aspects of cancer.The Society will encourage liaison and professional development among the medical, surgical, and allied scientists concerned with cancer.

Quynh-Thu Le, MDStanford Medicine

ARS 2016-2017 President

Dear Colleagues,

Welcome to the 99th Annual Meeting of the American Radium Society at the majestic Broadmoor Hotel in Colorado Springs. In keeping with our society’s mission, the scientific committee has organized an exceptional multi-disciplinary program. The theme will be “Clinical trial advancement through multidisciplinary integration of immunotherapy”. The Scientific Program Committee, chaired by Joseph Herman, MD, MSc, has recruited an outstanding cadre of lecturers and panelists. Keynote speakers include: Crystal L. Mackall, MD, Director of Parker Institute for Cancer Immunotherapy at Stanford University, and Walter J Curran, MD, FACR, Executive Director of the Winship Cancer Institute of Emory University and the Group Chairman of NRG Oncology. Dr. Mackall is an expert in cellular immune therapy and Dr. Curran is a seasoned clinical trialist. This year’s Janeway Lecturer will be James Allison, PhD, Vivian L. Smith Distinguished Chair in Immunology and Department Chair, Department of Immunology at MD Anderson Cancer Center. Dr. Allison is known in the field for his pioneering work of developing the first immune checkpoint therapy targeting CTLA-4. The success of this approach has led to significant investigation of immune checkpoint therapy being tested in different cancer types.

The meeting will kick off at noon on Saturday with James Cox, MD (Professor and previous Chair at MD Anderson), who will provide a personal perspective of how Colorado Springs was one of the early adopters of modern radiation oncology. Then, at 1 pm this year’s EduCase SBRT Primer will focus only on gastrointestinal (GI) and central nervous system tumors in order to provide a more in-depth “hands on” approach to treating these malignancies with SBRT. The Presidential Course highlighting clinical trials will start immediately after the SBRT Primer. We will have Howard Sandler, MD, speaking on genitourinary tumors, Karyn Goodman, MD, on GI cancers, Jeff Bradley, MD, on thoracic malignancies, Thomas Buccholtz, MD, on breast cancers, and Amanda Walker, MD, speaking on current clinical trials. Saturday evening, the Welcome Reception will include an exciting Poster Walk with a new format containing in-depth discussion of selected posters by pairs of expert faculty from 10 different disciplines from across the country.

The meeting features several exciting scientific panels, including a panel on state-of-the-art treatment of gynecologic malignancies led by Akila Viswanathan, MD, MPH, a panel on the management of esophageal cancers by Steven Lin, MD, and a panel on how to optimally combine SBRT with immunotherapy by Steven Chmura, MD, PhD There will also be an electrifying debate as to whether radiation is needed in the management of pancreatic cancer led by Daniel Chang, MD. There will be two case-based tumor boards, one on breast cancer developed by Kate Horst, MD and one on rectal cancer by Prajnan Das, MD, MS, MPH. Deviating from past traditions and in the spirit of patient-centered care, my Presidential Address will recognize one of the local CNN heroes, Brad Ludden from First Descents, a non-profit organization that brings life-changing outdoor adventures to young adult cancer fighters and survivors.

Of course, there will be several outstanding scientific sessions (assembled from a great selection of high-quality submissions). In addition, there will be many fun social events including a resident vs. faculty medical Jeopardy moderated by Join Luh, MD and David Raben, MD.

The annual meeting of the ARS is a great opportunity to blend learning, scientific discussions, collegial relationships, and leisure. Colorado Springs is a perfect place to get together. Located 60 miles south of Denver and situated near the base of one of the most famous American mountains, Pikes Peak, the city hosts 24 national governing bodies of sport, the US Olympic Committee, the US Olympic Training Center, and the Airforce Academy. It is home to many beautiful landscapes, miles of hiking trails, numerous local attractions, and lots of fun adventures. U.S. News and World Reports ranks Colorado Springs the 6th “Best Weekend Getaway” and the 5th “Best Place to Live” in the US. In addition, it has significant historic importance to cancer because it is home to one of the first radiation oncology facilities in North America. Dr. Henry Coutard was a founder of the Penrose Tumor Institute in 1941 and his protégé Dr. Juan del Regato was the medical director of the Penrose Cancer Hospital for many years. Many world-renowned radiation oncologists were trained there including our own Dr. James Cox, one of the past ARS presidents.

Finally a special thank you to the following companies for providing educational grants in support of the 99th Annual Meeting: Varian Medical Systems, Platinum Level Sponsor; Elekta, Silver Level Sponsor; Hitachi America, Ltd, Silver Level Sponsor; Mevion Medical Systems, Silver Level Sponsor; AstraZeneca, Bronze Level Sponsor; ViewRay, Inc., Bronze Level Sponsor; and Bayer.

Best regards,

Quynh-Thu Le, MDARS President

1

Table of Contents

1

234567891213141516171829

Room Assignments

On-Site Registration HoursColorado Hall LobbySaturday, May 6, 2017: 10:00am - 5:30pmSunday, May 7, 2017: 6:30am - 1:30pmMonday, May 8, 2017: 7:00am - 1:00pmTuesday, May 9, 2017: 7:00am - 11:30am

Exhibit Hall/Poster HoursColorado Hall ABCSaturday, May 6, 2017 Opening Reception 5:15pm - 6:15pm Poster Walk 6:15pm - 7:00pmSunday, May 7, 2017 7:00am - 12:30pmMonday, May 8, 2017 7:00am - 12:30pmTuesday, May 9, 2017 7:00am - 12:30pm

Speaker Ready Room HoursColorado Hall OfficeSaturday, May 6, 2017 10:00am- 5:30pmSunday, May 7, 2017 6:30am - 5:00pmMonday, May 8, 2017 6:30am - 4:10pmTuesday, May 9, 2017 6:30am - 12:00pm

Hospitality/Spouses SuiteEverest Cottage #3981Sunday, May 7, 2017 7:00am - 11:30amMonday, May 8, 2017 7:00am - 11:30amTuesday, May 9, 2017 7:00am - 11:30am

Who Should AttendThe ARS meeting is open to ARS Members and Non-Members, specializing or training in the field of Oncology including, but not limited to, Medical Oncology, Surgical Oncology, Radiation Oncology, Gynecologic Oncology, Head and Neck Oncology, and all other specialties within the field of Oncology, as well as Allied Health and Industry Corporate Leaders.

Speaker Ready Room Colorado Hall OfficeRegistration Colorado Hall LobbyGeneral Session Colorado Hall DEExhibit Hall and Posters Colorado Hall ABCResident Lunch Donald Ross Room (Golf Club)Spouses Lounge Everest Cottage #3981Tumor Boards Colorado Hall F

General Information

Message from the President General InformationCME InformationMeeting LeadershipARS LeadershipBecome a MemberHotel MapSpecial SessionsExhibitsJaneway LectureKeynote SpeakersAwardsSchedule at a GlanceFaculty & ModeratorsDisclosuresScientific ProgramPoster Listing

2

CME Information

Claim Your CMEsTo claim your CME credits, please complete the following evaluation at https://www.research.net/r/ars2017evaluationAll attendees who intend to claim CME credit MUST complete the evaluation by Friday June 2, 2017. The meeting evaluation must be completed in order to receive a CME Certificate. Please allow 2-4 weeks for processing before your certificate arrives.

Self Assessment Modules (SAM) “Qualified by the American Board of Radiology in meeting the criteria for self-assessment toward the purpose of fulfilling requirements in the ABR Maintenance of Certification Program.” ARS is proud to offer SAMs for the 2017 Meeting in a robust quantity on many topics. Self-Assessment Modules count toward the SAM requirement for the ABR and some other specialty boards.

For more information and to take the Self Assessment Exams, please visit https://www.americanradiumsociety.org/ars-education/sams-2017/

Educational Learning Objectives At the end of this activity, participants will be able to: 1.

2. 3. 4.

Outcomes This educational activity will improve competence, practice performance and patient outcomes by: 1.

2.

3.

4.

Reviewing sophisticated radiotherapy techniques and documenting when and for which patients such techniques/technologies have a beneficial role for gynecological, breast, and gastrointestinal malignancies.Documenting and elucidating the role of multimodality care in the contemporary management of esopha-geal and rectal cancer.Educating physicians as to the most appropriate approaches for gynecological, breast, gastrointestinal, liver, and oligometastatic disease.Reviewing the literature regarding the appropriate application of stereotactic body radiation therapy and its safe delivery for liver, pancreas and CNS tumors.

Directly care for patients with gynecologic, breast, esophageal, and rectal cancer in a multidisciplinary environment.Review the role of radiation therapy in the management of complex cases of localized pancreas cancer.Identify and care for patients with oligometastatic disease.Analyze the issues involved in the application of stereotactic body radiation therapy in gastrointestinal and CNS malignancies.

3

Meeting Leadership

A Message from the Program Chair

Joseph Herman, MD, MScProfessor, MD Anderson Cancer Center ARS Scientific Program Chair

Dear Colleagues,

It’s my great pleasure and honor to welcome you to the 2017 American Radium Society meeting!

We have a terrific scientific program planned out for you. I would first like to take this opportunity to thank all of our speakers, panelists, moderators and presenters. Special thanks to Dr. Quynh Le, our ARS President, for all of her support, as well as our entire ARS Scientific Program Committee, for their hard work and dedication. Our ARS staff deserves credit for all their help in organizing the many details of this meeting.

We have created a diverse program this year that includes Self Assessment Module credits, a special SBRT Primer on GI and CNS tumors, a timely debate on the management of pancreas cancer, and new panels on breast and rectal cancer. Throughout this meeting, you will see aspects of our theme: “Clinical Trial Advancement through Multidisciplinary Integration of Immunotherapy”. Specifically our program includes National and International experts in clinical trial development and scientific breakthroughs in immunology. In addition, we have a session dedicated towards oligometastatic disease with a focus on multidisciplinary integration with radiation and immunotherapy. The scientific programs include novel, cutting edge original research from students, residents and faculty.

Most of all, please take this opportunity to interact with your colleagues and friends here at the meeting in a relaxed family-friendly environment. Join us as we enjoy the beautiful outdoors of Colorado Springs!

Sincerely,

Executive Committee 2016 - 2017

Quynh-Thu Le, MDPresident

Ben Slotman, MD, PhDPresident Elect

Benjamin Movsas, MDSecretary

Andre Konski, MDTreasurer

Kaled M. Alektiar, MDIndustry Relations Chair

Erich M. Sturgis, MD, MPHMember at Large

Wade Thorstad, MDMember at Large

Joseph Herman, MD, MSc2017 Scientific Program Chair

John A.”Drew” Ridge, MD, PhDImmediate Past President

2017 Scientific Program Committee

Joseph Herman, MD, MSc, SPC Chair

Quynh-Thu Le, MD, ARS President

Matt Abramowitz, MD Beth M. Beadle, MD, PhD

Richard Bleicher, MD Thomas Buchholz, MD

Mark Buyyounouski, MD, MS Eric Chang, MD

James D. Cox, MD Ted DeWeese, MD

Gary Freedman, MD Thomas Galloway, MD

Mary K. Hayes, MD Mark A. Henderson, MD

Peter A.S. Johnstone, MD Josh Meyer, MD

Ritsuko Komaki, MDAndre Konski, MD, MBA,

FACR Ben Movsas, MD

Rahul R.Parikh, MD Alan Pollack, MD, PhD

John “Drew” Ridge, MD, PhD Ken Roberts, MD

Kenneth E. Rosenzweig, MD Elin R. Sigurdson, MD, PhD

Ben Slotman, MD, PhD Charles Thomas, MD

Charles Simone, MD, PhD Akila Viswanathan, MD

4

ARS Leadership

Past Presidents of the ARS

1916 W.H.B. Aikins, MD* 1917 W.H.B. Aikins, MD* 1918 John M. Lee, MD* 1919 J.B. Bissell, MD* 1920 Henry K. Pancoast, MD* 1921 Henry Schmitz, MD* 1922 G.E.Pfahler, MD* 1923 Robert F. Loucks, MD* 1924 James T. Case, MD* 1925 WilliamS.Newcomet, MD* 1926 Douglas Quick, MD* 1927 Albert Soiland, MD* 1928 Curtis F. Burnam, MD* 1929 Edwin C. Ernset, MD* 1930 Harry H. Bowing, MD* 1931 Henry J. Ullmann, MD* 1932 Sanford Withers,MD* 1933 Burton J. Lee, MD* 1934 Rollin H. Stevens, MD* 1935 William H. Cameron, MD* 1936 George W. Grier, MD* 1937 Zoe A. Johnston, MD* 1938 Edward H. Skinner, MD* 1939 William P. Healy, MD* 1940 Lawrence A. Pomeroy, MD* 1941 Frederick W. O’Brien, MD* 1942 Hayes E. Martin, MD* 1946 William E. Costolow, MD* 1947 Charles L. Martin, MD* 1948 A.N. Arneson, MD* 1949 Maurice Lenz, MD* 1950 William S. MacComb, MD* 1951 Leland R. Cowan, MD* 1952 Hugh F. Hare, MD* 1953 Howard B. Hunt, MD* 1954 Edith H. Quimby, ScD* 1955 John E. Wirth, MD*1956 Grant Beckstrand, MD* 1957 Norman A. McCormick, MD* 1958 Douglas J. Roberts, MD* Ralph T. Ogden, MD* 1959 Milford D. Schulz , MD* 1960 Theodore R. Miller, MD* 1961 Jesshill Love,MD* 1962 Robert L. Brown, MD* 1963 Gilbert H. Fletcher, MD* 1964 Charles G. Stetson, MD* 1965 Joseph H.Farrow, MD* 1966 Justin J. Stein, MD* 1967 Milton Friedman, MD*

* Deceased

Executive Committee Quynh-Thu Le, MD, President 2016-2017Ben Slotman, MD, PhD, President Elect 2016-2017Benjamin Movsas, MD, Secretary 2016-2018Andre Konski, MD, Treasurer 2015-2017Kaled M. Alektiar, MD, Industry Relations Chair 2015-2019Erich M. Sturgis, MD, MPH, Member at Large 2016-2018Wade Thorstad, MD, Member at Large 2015-2017Joseph Herman, MD, 2017 Scientific Program Chair 2016-2017John A. “Drew” Ridge, MD, PhD, Immediate Past President 2016-2017

Constitution & Bylaws Committee Kenneth Russell, MD, Chair 2015-2018Seungtaek Choi, MD 2016-2019Arnold Paulino, MD 2015-2018John A. “Drew” Ridge, MD, PhD, 2016-2017

Education & Website Resources Committee Jonathan J. Beitler, MD, Chair 2014-2017Roy Decker, MD 2014-2017Jiade Lu, MD 2015-2018Mike Kupferman, MD 2014-2017Gary Freedman, MD 2016-2018Charles R. Thomas, MD 2016-2019Cynthia Ballenger, MD 2014-2017Quynh-Thu Le, MD, President, Ex-Officio 2016-2017

Industry Relations/Development Committee Kaled M. Alektiar, MD (Chair) 2015-2019Meena Moran 2015-2019Jeffrey D. Bradley, MD 2016-2020Sue S. Yom, MD PhD 2014-2018Cynthia Ballenger, MD 2015-2019Theodore L. DeWeese, MD 2016-2020Quynh-Thu Le, MD, President, Ex-Officio 2016-2017

Janeway Lecture Committee Peter A.S. Johnstone, MD 2014-2017Jay Cooper, MD 2015-2018Eric L. Chang, MD 2016-2019

Membership & Credentials Committee Benjamin Movsas, MD (Chair) 2016-2018Mike Kupferman, MD 2014-2017Kevin McMullen, MD 2016-2019Ray Sawaya, MD 2015-2018Beth M. Beadle, MD, PhD 2016-2019Meena S. Moran, MD 2014-2017Matthew C. Abramowitz, MD 2014-2017Arnold C. Paulino, MD 2012-2015Ehab Hanna, MD 2016-2019Quynh-Thu Le, MD, President, Ex-Officio 2016-2017

Nominating Committee Kenneth Russell, MD 2014-2017Kenneth Roberts, MD 2015-2018Steve Hahn, MD 2016-2019

Awards Committee Ashesh B. Jani, MD 2014-2017Joe Herman, MD 2014-2017Charles Thomas 2015-2018Quynh-Thu Le, MD, President, Ex-Officio 2016-2017

2016-2017 Scientific Program CommitteeJoseph Herman, MD, SPC ChairQuynh-Thu Le, MD, ARS PresidentMatt Abramowitz, MD,Beth M. Beadle, MD, PhDRichard Bleicher, MDThomas Buchholz, MDMark Buyyounouski, MD, MSEric chang, MDJames D. Cox, MDTed DeWeese, MDGary Freedman, MDThomas Galloway, MDMary K. Hayes, MDMark A. Henderson, MDPeter A.S. Johnstone, MDJosh Meyer, MDRitsuko Komaki, MDAndre Konski, MD, MBA, MA, FACRBen Movsas, MDRahul R. Parikh, MDAlan Pollack, MD, PhDJohn “Drew” Ridge, MD, PhDKen Roberts, MDKenneth E. Rosenzweig, MDElin R. Sigurdson, MD, PhDBen Slotman, MD, PhDCharles Thomas, MDCharles Simone, MD, PhDAkila Viswanathan, MD

Representative to the Board of Chancellors of the American College of Radiology Peter A.S. Johnstone, MD 2014-2017

The UICC Global Task Force on Radiotherapy for Cancer Control (GTFRCC) Ritsuko Komaki 2015-2017

American College of Radiology Councilor Frank Wilson 2015-2018

American College of Radiology Assistant Councilor Jeff Michalski 2015-2018

Representative to the Commission on Cancer John “Drew” Ridge, MD, PhD 2014-2017

Representative to the National Council on Radiation Protection & MeasurementsRitsuko Komaki, MD 2014-2017

Trustees of the American Board of RadiologyTom Buchholz 2015-2019

5

Become a Member

Past Presidents of the ARS

1968 John L. Pool, MD*1969 Juan A. del Regato, MD*1970 Fernando Bloedorn, MD*1971 James F. Nolan, MD*1972 John V. Blady, MD*1973 Antolin Raventos, MD*1974 Jerome M. Vaeth, MD*1975 Victor A. Marcial, MD*1976 Felix Rutledge, MD*1977 Luther W. Brady, MD1978 Richard H. Jesse, MD*1979 Frederick W. George III, MD* 1980 Alfred S. Ketcham, MD1981 Simon Kramer, MD*1982 George C. Lewis, Jr, MD*1983 Morton M. Kligerman, MD* 1984 Seymour H. Levitt, MD1985 John R. Durant, MD*1986 Frederick Eilber, MD1987 Gerald E. Hanks, MD1988 Morris J. Wizenberg, MD* 1989 Carl M.Mansfield,MD1990 Elliot W. Strong, MD1991 Robert G. Parker, MD*1992 J. Taylor Wharton, MD1993 Lawrence W. Davis, MD1994 Peter H. Wiernik, MD1995 Marvin Rotman, MD1996 Robert M. Byers, MD1997 H. Rodney Withers, MB, BS* 1998 ThomasW.Griffin,MD1999 David H. Hussey, MD*2000 Eric J. Hall, DPhil, DSc2001 David M. Gershenson, MD 2002 Jay S. Cooper, MD2003 J. Frank Wilson, MD2004 James D. Cox, MD2005 .Martin Colman, MD2006 Randal Weber,MD2007 Jonathan J. Beitler, MD, MBA 2008 Ritsuko U. Komaki, MD2009 Bruce G. Haffty, MD2010 Raymond Sawaya, MD2011 Peter A.S. Johnstone, MD2012 Alan Pollack, MD, PhD2013 Thomas Buchholz, MD2014 Elin R. Sigurdson, MD, PhD 2015 Kenneth E. Rosenzweig ,MD 2016 John A. ‘Drew’ Ridge, MD, PhD

* Deceased

The world’s first organization dedicated to the multidisciplinary

treatment of cancer. Mission Statement The Mission of The Society is to promote the multi-disciplinary and collegial study of all aspects of cancer. The Society will encourage liaison and professional development among the medical, surgical, and allied scientists concerned with cancer.

Who Joins the ARS? The American Radium Society (ARS), a venerable institution and the oldest society devoted to the study and treatment of cancer, is a multidisciplinary organization with members from a number of specialized fields including: - Radiation Oncology - Surgical Oncology - Gynecological Oncology - Medical Oncology - Allied Science - Medical Physics - Various fields of Oncology

Our Member Benefits ARS membership offers a range of member benefits including: -

- -

-

-

- - -

Apply for MembershipComplete an online application today atwww.americanradiumsociety.org/membership/application/

Applications are accepted and reviewed throughout the year.

An ARS Member Services Team member is ready to assist you. If you have questions call us at 310-437-0581 x 138 M-F, 8 AM-5 PM Pacific Standard Time or email: membership@americanradiumsociety.org

Our signature event, the ARS Annual Meeting that rotates among amazinglocations while offering 4 days of networking, state-of-the-art surgical technology and techniques and over 18 hours of Category 1 CME.Discounted registration fees for attendance at the ARS Annual Meeting.Online Self Assessment Modules (SAMs) are educational sessions thatinclude self-administered examinations to improve your skills,knowledge, patient care, and practice performance. Self assessmentcredits are an essential element of Maintainence of Certification. Youwill earn value-added CME credit for your participation in each session.As a member, your SAMs are FREE! You must register for the annualmeeting’s scientific session in order to participate in the SAMs.Opportunities to apply for the Young Oncologist Essay Award and TravelGrant Awards.A membership certificate for display in your home or office.Discounted rental rates for the ARS Membership Mailing List.And, much more.

6

Hotel Map

Special Services The American Radium Society wishes to ensure that no individual with a disability is excluded, denied services, segregated or otherwise treated differently because of the absence of auxiliary aids and services. If you require auxiliary aids or service, please indicate your needs at the ARS registration desk. Please direct all questions concerning registration to the Meeting Registrar at 310-437-0581 x 128 or registration@americanradiumsociety.org

Meeting LocationsA Colorado HallB Broadmoor SouthC Golf Club/SpaD Everest Cottage

7

Special Sessions

The ARS would like to thank the following companies for providing educational grants in support of the 99th Annual Meeting:

* Supporters as of May 2017

THANK YOU TO OUR 2017 SUPPORTERS!

Varian Medical Systems Industry Symposium Healthcare Reform 2017:

What does it mean for Radiation Oncology?Sunday, May 7, 2017 4:00pm - 5:30pm

Colorado Hall DE* * This activity is not part of the official ARS scientific program.

A lively discussion with national experts describing the current status, controversies, and future of healthcare reform as it relates to Radiation Oncology.

What’s new in Washington and how does it impact Radiation Oncology?

Stacy Stordahl, Senior Director, Varian Government Affairs

MACRA, what is it and why should I care?Join Luh, MD, Radiation Oncologist, St. Joseph Health

Quality of care, guidelines, and appropriateness criteria: American Radium Society’s evolving role.Sue Yom, MD, Associate Professor, Radiation Oncology, UCSF

ViewRay, Inc. Industry Symposium Global Perspectives on MRI-Guided Radiation Therapy: U.S. and

European MRIdian® Centers Tell AllMonday, May 8, 2017 4:00pm - 5:30pm

Colorado Hall DE* * This activity is not part of the official ARS scientific program.

Come hear clinicians from leading institutions within Europe and the United States discuss their experience with MRIdian®,

the world’s first and only clinical MRI-guided radiation therapy system. Everything from implementation and quality assurance to on-table adaptive therapy and patient outcomes will be addressed. This is a symposium you won’t want to miss!

Presenters include:

Jeffrey Bradley, MD from Washington University School of Medicine, St. LouisBen Slotman, MD PhD from VU University Medical Center, Amsterdam

Moderated by Matthew Abramowitz, MD from The University of Miami, Sylvester Comprehensive Cancer Center

8

PLATINUM LEVELVarian Medical Systems

SILVER LEVELElekta, Inc.

Hitachi America, Ltd.Mevion Medical Systems

BRONZE LEVELAstraZenecaViewRay, Inc.

SPONSORSHIP: RESIDENT JEOPARDYVarian Medical Systems

SPONSORSHIP: KEYNOTE LECTURE – DR. CRYSTAL L. MACKALL

Bayer

Exhibits

Bayer #4100 Bayer Blvd.Whippany, NJ 07981Tel: 862-404-3000Web: www.pharma.bayer.com

Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now includes three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.

Best Medical International #67643 Fullerton RoadSpringfield, VA 22153Tel: 703-451-2378Web: www.teambest.com

Best Medical manufactures Best® Iodine-125, Best® Palladium-103, Iridium-192 and Gold-198 seeds, along with HDR accessories, fiducial markers, Best® Brachytherapy Kits and other products. Seeds are available either loose or loaded in cartridges, needles or strands, and are available sterile or non-sterile. Best Medical can make catheters, needles, templates and applicators to meet your special needs.

Brainlab #205 Westbrook Corporate Center, Ste1000Westchester, IL 60154Tel: 708-409-1343Web: www.brainlab.com

Brainlab develops, manufactures and markets software-driven medical technology, enabling access to advanced, less invasive patient treatments. Brainlab technology powers treatments in radiosurgery as well as neurosurgery and other surgical fields.

AstraZeneca #161 Medimmune WayGaithersburg, MD 20878 Tel: 301-398-1457 Web: www.astrazeneca.com

AstraZeneca/MedImmune’s Approach to Immuno-Oncology (IO) is anchored by immunotherapies that have been designed to overcome anti-tumor immune suppression. Durvalumab, an anti-PD-L1 antibody, is being investigated in an extensive clinical trial program - as monotherapy or in combination with tremelimumab, our anti-CTLA-4 antibody, or a range of small targeted molecules - in multiple tumor types. We believe IO therapies will offer the potential for life-changing anti-cancer treatments.

Augmenix #8201 Burlington RoadBedford, MA 01730Tel: 781-895-3235Web: www.spaceoar.com

Augmenix is a medical technology company that develops proprietary absorbable PEG hydrogels that separate and protect organs at risk during radiotherapy. The SpaceOAR System provides a barrier between the prostate and rectum to decrease rectal toxicity and minimize changes in quality of life (QOL) following prostate radiotherapy. The 3-year follow-up study results of a Phase 3 clinical trial recently published in the April 2017 Red Journal, demonstrated a significant reduction in late rectal toxicity (78%) along with favorable bowel, urinary and sexual QOL measurements. SpaceOAR System is FDA cleared, CE marked, approved in Australia and licensed in Canada.

Accuray, Inc. #131310 Chesapeake TerraceSunnyvale, CA 94089Tel: 408-716-4600Web: www.accuray.com

Accuray is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company’s leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.

Accuray, Inc. AstraZeneca Augmenix Bayer Best Medical International Brainlab Bristol-Myers Squibb CDR Systems Elekta Gold Anchor/Naslund Medical, Inc.. Hitachi America, Ltd. IBA, Inc. Merck Mevion Medical Systems Orfit Industries America Philips ViewRay, Inc.

EXHIBITORS TABLE

#13#16#8 #4#6

#20#11#14#15

#5#3#12#7#17#1-2#19#18

9

Exhibits

Hitachi America, Ltd. #350 Prospect AvenueTarrytown, NY 10591Tel: 914-332-5800Web: www.hitachi-america.us

Hitachi markets customized particle therapy solutions with the following features that have been demonstrated by prestigious users worldwide:-Proton or carbon ions-Choice of full or compact gantries-Spot scanning IMPT-3D image guidance: CBCT or CT-on-Rails-Integrated target tracking-Single or multi-room configurations-Dedicated service and maintenance team

IBA, Inc. #122000 Edmund Haley Drive, Suite 210Reston, VA 20191Tel: 215-615-5150Web: www.ibaworldwide.com

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, which is considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1300 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Elekta #15400 Perimeter Center Terrace, Ste 50Atlanta, GA 30346 Tel: 770-670-2374 Web: www.elekta.com

Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm.

Gold Anchor #5Naslund Medical, Inc.150 N. Michigan Avenue, Ste 1950Chicago, IL 60601Tel: 312-212-3470Web: www.GoldAnchorMarker.com

Gold Anchor is a great fiducial marker: our industry leading thin needles enable safe implantation in almost any inner organ; the unique folding marker design allows shortened lead time between implantation and CT/MRI; and the patented marker material (0.5% pure iron in an alloy with gold) provides enhanced MRI visibility.

Vassvagen 21Huddinge, Sweden 14139Web: www.GoldAnchorMarker.com

Bristol-Myers Squibb #11345 Park AvenueNew York, NY 10154Tel: 800-332-2056Web: www.bms.com

CDR Systems #144334 110th Avenue SECalgary, AB T2C 0J6CANADATel: 855-856-7035Web: www.cdrsys.ca

Founded in 2002, CDR has become a global leader in designing and manufacturing world-class & exceptionally innovative patient positioning systems and associated consumables to radiation oncology centers of all sizes CDR is focused on accuracy, reproducibility and patient comfort. Whether you are a freestanding cancer center or a hospital-based healthcare provider, CDR is able to deliver leading-edge solutions and services for treatments including prone and supine breast, prostate, SBRT, abdominal compression, frameless Cranial SRS, IGRT Head & Neck as well as all associated peripherals such as thermoplastic masks, Vacuum Lock cushions & pumps, waterbaths and ovens, bolus and a range of positioning wedges and supports.

10

Exhibits

Philips #19595 Miner RoadHighland Heights, OH 44143Telephone: 440-483-4737Website: www.philips.com

Philips aims to support healthcare professionals delivering more efficient cancer care at lower cost; we do this by constantly looking at better ways to locate cancers earlier, diagnosing them more precisely, making therapies more precise and minimal invasive, and taking a personalized approach in giving the patient the best possible care.

Merck #72000 Galloping Hill RoadKenilworth, NJ 07033Tel: 908-740-4000Web: www.merck.com

Mevion Medical Systems #17300 Foster StreetLittleton, MA 01460Tel: 978-540-1500Web: www.mevion.com

The MEVION S250 Series offers the smallest, most advanced proton therapy solution available today. Its unique gantry-mounted proton accelerator provides superior treatment delivery, reduces complexity and cost, and significantly streamlines operations. No other proton therapy system can match the quality, size, cost and efficiency of the MEVION S250 Series.

Orfit Industries America #1-2350 Jericho Turnpike, Suite 302Jericho, NY 11753Tel: 516-935-8500Web: www.orfit.com

Orfit is a world leader in supplying High Precision Patient Immobilization Systems for Head, Neck and Shoulders using a Frameless Open Face Mask System. MammoRx Breast Boards, SBRT and Prone Breast Solutions. Systems for Extremities, Pelvis/Abdomen, Proton Therapy, MR as well as a comprehensive range of pediatric systems.

Colorado A

Colorado B

Colorado C

12 13 14 15 16 17

234567

8

9

10

1920

1

11

18

Food & Beverage

Exhibit Floor PlanColorado Hall ABC

ViewRay, Inc. #18815 E. Middlefield RoadMountain View, CA 94043Telephone: 408-396-2355Website: www.viewray.com

ViewRay®, Inc. (NASDAQ:VRAY), designs, manufactures, and markets the MRIdian® radiation therapy system. MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors during radiation. ViewRay believes this combination of enhanced visualization and accuracy will significantly improve outcomes for patients.

11

Janeway Lecture

As an immunologist, Dr. James Allison’s fundamental discoveries include the definition of the structure of the T cell antigen receptor, demonstration that the T cell molecule CD28 provides costimulatory signals necessary for full T cells activation, and that the molecule CTLA-4 is an inhibitory checkpoint which inhibits activated T cells. He proposed that immune checkpoint blockade might be a powerful strategy for therapy of many cancer types, and conducted preclinical experiments showing its potential. He was involved in the development of ipilimumab, which was approved by the FDA for treatment of metastatic melanoma in 2011. His development of the concept of immune checkpoint blockade has transformed cancer therapy and saved thousands of lives. Dr. Allison is a member of the National Academy of Sciences and the National Academy of Medicine. He has received numerous awards, including the Lifetime Achievement Award from the American Association of Immunologists, the Lloyd J. Old Award and Pezcoller Foundation-AACR International Award from the American Association for Cancer Research, the Novartis Award for Clinical Immunology, the Medal of Honor in Basic Research from the American Cancer Society, the Harvey prize in Human Health from the Israeli Insitute of Technology, the Economist Magazine Innovation Prize for Biomedicine, the Breakthrough Prize in Biosciences, the Szent-Gyorgyi Prize for Progress in Cancer Research, and Lasker-Debakey Clinical Medical Research Award, and the Wolf Prize in Medicine.

The Janeway Medal The heraldry of the Janeway Medal is drawn from Norse Mythology: Odin, the Allfather with power over the precious minerals of the earth, sought enlightenment for the sons of men. He traveled to Mimir’s Well where Wisdom and Wit lodged hidden. The face of the Janeway Medal shows Odin standing before the giant Mimir, warden of the well, yielding one of his eyes for a draught of the precious water. The reverse side of the medal shows Odin’s two ravens, who spent the day flying throughout the expanse of the universe: Hugin (Thought-Reflection) and Munin (Memory-Remembrance). The ravens returned each evening to perch on Odin’s shoulders and whisper in his ears the events and progress observed. Odin’s physical privation, as a price for wisdom, is symbolic of the self-sacrifice of the heroic pioneers of radium therapy for cancer.

Odin’s ravens, as shown on the Janeway Medal, have become the symbols of the American Radium Society. Since 1933, the American Radium Society has sponsored an annual lecture in memory of Doctor Henry H. Janeway (1873-1921), a great American pioneer in the therapeutic use of radium. Originally a large bronze medal, the Janeway Medal was changed to a gold medal in 1971. A special committee of the Society chooses the lecturers on the basis of their outstanding scientific contributions. Each lecturer is presented with the handsome Janeway Medal.

James P. Allison, PhDMD Anderson Cancer Center

12

Keynote Lectures

Walter J. Curran, Jr., MD, FACR is the Executive Director of the Winship Cancer Institute of Emory University (Winship), the first and only National Cancer Institute-designated cancer center in the state of Georgia. He also serves as the Lawrence W. Davis Professor and Chairman in Emory’s Department of Radiation Oncology. He is considered an international expert in the management of patients with locally advanced lung cancer and malignant brain tumors. He has led several landmark clinical and translational trials in both areas and is responsible for defining a universally adopted staging system for patients with malignant glioma. He currently serves as a group chairman and a principal investigator of NRG Oncology, the largest of the five National Cancer Institute-funded clinical trials network group.

Dr. Curran is the first radiation oncologist to serve as Director of a National Cancer Institute-designated cancer center. Dr. Curran is a member of the board of directors of the American Society of Clinical Oncology (ASCO). He was also named a Georgia Research Alliance Eminent Scholar and Chair in Cancer Research in 2013.

Before joining Emory, Dr. Curran was Professor and Chairman of Radiation Oncology at Thomas Jefferson University (Jefferson) in Philadelphia and Clinical Director of Jefferson’s Kimmel Cancer Center.

Crystal L. Mackall, MD is Professor of Pediatrics and Internal Medicine at Stanford University. She serves as Associate Director of Stanford Cancer Institute and Leader of the Cancer Immunology and Immunotherapy Program at Stanford. During her tenure as Head of the Immunology Section and Chief of the Pediatric Oncology Branch, NCI, she built an internationally recognized translational research program spanning basic studies of T cell homeostasis and tumor immunology and clinical trials of immune based therapies for cancer. Her work is credited with identifying an essential role for the thymus in human T cell regeneration and discovering IL-7 as the master regulator of T cell homeostasis. She has led numerous cutting edge and first-in-human and first-in-child clinical trials spanning dendritic cell vaccines, cytokines, and adoptive immunotherapy using NK cells and genetically modified T cells. Her group was among the first to demonstrate impressive activity of CD19-CAR in pediatric leukemia and work for her laboratory was among the first to identify T cell exhaustion as a major factor limiting the efficacy of this novel class of therapeutics. Dr. Mackall’s clinical trials are notable for the incorporation of deep biologic endpoints that further our understanding of the basis for success and failure of the agent under study. She has published over 150 manuscripts in peer-reviewed journals and serves in numerous leadership positions, including co-Leader of the StandUp2Cancer Pediatric Dream Team and Director, Parker Institute for Cancer Immunotherapy. She is Board Certified in Pediatrics and Internal Medicine.

Walter J. Curran, Jr., MD, FACRWinship Cancer Institute of Emory University

Crystal L. Mackall, MDStanford University

13

Essay Awards and Travel Grants

Young Oncologist Essay AwardsProgram Number: S039Presenter: Ehsan H BalagamwalaAbstract Title: RECURSIVE PARTITIONING ANALYSIS IS PREDICTIVE OF OVERALL SURVIVAL FOR PATIENTS UNDERGOING SPINE STEREOTACTIC RADIOSURGERY

Program Number: S040Presenter: Nicholas C Lee, BScAbstract Title: THE RISK OF LEVEL IB NODALINVOLVEMENT IN OROPHARYNX CANCER: GUIDANCE FOR SUBMANDIBULAR GLAND SPARING IRRADIATION

Program Number: S041Presenter: Arpan V Prabhu, BSAbstract Title: ONLINE PALLIATIVE CARE PATIENT EDUCATION RESOURCES: DO THEY MEET NATIONAL HEALTH LITERACY RECOMMENDATIONS?

Program Number: S042Presenter: Renae D Van Wyhe, MBAAbstract Title: INVASIVE LOBULAR CARCINOMA PREDICTS FOR AN INCREASED LIKELIHOOD OF SURGICAL UPSTAGING REQUIRING POST-MASTECTOMY RADIATION THERAPY

Program Number: S043Presenter: Vincent BernardAbstract Title: HETEROGENEITY IN TREATMENT RESPONSE OF SPINE METASTASES TO SPINE STEREOTACTIC RADIOSURGERY WITHIN “RADIOSENSITIVE” SUBTYPES

14

Travel GrantsProgram Number: S001 Presenter: Jason K Molitoris, MD, PhDAbstract Title: REGIONAL NODAL IRRADIATION IN ELDERLY NODE POSITIVE WOMEN: A PATTERNS OF CARE STUDY ON CHANGES IN UTILIZATION OVER A DECADE Program Number: S019 Presenter: Penny Fang, MDAbstract Title: LYMPHOCYTE-SPARING EFFECT OF PROTON THERAPY IN PATIENTS WITH ESOPHAGEAL CANCER Program Number: S024 Presenter: Adam Bossert, BSAbstract Title: EXTRACAPSULAR EXTENSION IS ASSOCIATED WITH WORSE DISTANT CONTROL AND PROGRESSION-FREE SURVIVAL IN PATIENTS WITH LYMPH NODE-POSITIVE HUMAN PAPILLOMAVIRUS-RELATED OROPHARYNGEAL CARCINOMA Program Number: S029 Presenter: Goran MicevicAbstract Title: DEVELOPMENT OF AN IMMUNE-ASSOCIATED MOLECULAR SIGNATURE PREDICTING MELANOMA SURVIVAL Program Number: S031 Presenter: Arya AminiAbstract Title: RACIAL DISPARITIES IN PROTON BEAM THERAPY UTILIZATION IN THE UNITED STATES Program Number: S045 Presenter: David R Raleigh, MD, PhDAbstract Title: LOSS OF H3K27 TRIMETHYLATION IS PROGNOSTIC FOR WORSE OUTCOMES FROM MENINGIOMA

Program Number: S049 Presenter: Garrett JensenAbstract Title: INTERNAL VALIDATION OF THE PROGNOSTIC INDEX FOR SPINE METASTASIS (PRISM) FOR STRATIFYING SURVIVAL IN PATIENTS TREATED WITH SPINAL STEREOTACTIC RADIOSURGERY Program Number: P016 Presenter: Erqi PollomAbstract Title: A PHASE I/II TRIAL OF 5-FRACTION STEREOTACTIC RADIOSURGERY WITH 5MM MARGINS WITH CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN NEWLY DIAGNOSED SUPRATENTORIAL GLIOBLASTOMA: QUALITY OF LIFE AND UPDATED OUTCOMES Program Number: P038 Presenter: Anna Lee, MD, MPHAbstract Title: COMPARISON OF NEOADJUVANT VERSUS CONCURRENT/ADJUVANT INITIATION OF ANDROGEN DEPRIVATION IN MEN WITH HIGH-RISK PROSTATE CANCER RECEIVING DEFINITIVE RADIATION THERAPY Program Number: P074 Presenter: John V Hegde, MDAbstract Title: PATIENT-REPORTED QUALITY OF LIFE OUTCOMES AFTER DE-ESCALATED CHEMORADIATION FOR HPV-POSITIVE OROPHARYNGEAL CARCINOMA: FINDINGS FROM A PHASE II TRIAL

Schedule-at-a-Glance

15

Saturday, May 6, 201712:00 - 1:00 PM Resident Lunch Donald Ross Room1:00 - 3:00 PM EduCase SBRT eContouring Symposium (SAM) Colorado Hall DE3:15 - 5:30 PM Presidential Categorical Course - Clinical Colorado Hall DE Trials (SAM) 5:15 - 6:15 PM Opening Reception in Exhibit Hall Colorado Hall ABC6:15 - 7:00 PM Poster Walk Colorado Hall ABC

Sunday, May 7, 20177:00 - 7:30 AM Continental Breakfast Colorado Hall ABC 7:30 - 8:30 AM Updates in the Management of Cervical Cancer (SAM) Colorado Hall DE 8:30 - 9:30 AM Janeway Lecturer: Immune Blockade in Cancer Colorado Hall DE Therapy: New Insights and Opportunities James P. Allison, PhD - MD Anderson Cancer Center 9:30 - 10:30 AM Scientific Session # 1: Breast /Gyn Colorado Hall DE10:30 - 10:45 AM Break in Exhibit Hall Colorado Hall ABC10:45 - 12:00 PM Scientific Session # 2: Lung/Lymphoma Colorado Hall DE12:00 - 1:00 PM Oligometastatic and Immunotherapy Panel (SAM) Colorado Hall DE1:15 - 2:45 PM Case-Based Tumor Board: Breast Cancer *(SAM) Colorado Hall F4:00 - 5:30PM Varian Medical Systems Industry Symposium Colorado Hall DE This activity is not part of the official ARS scientific program.

5:30 - 7:00PM Resident vs Faculty Medical Jeopardy Colorado Hall DE7:30 - 9:30 PM ARS Social Event at the Cheyenne Lodge** Shuttle leaves from Broadmoor South at 7:20pm

Monday, May 8, 20177:00 - 7:30 AM Continental Breakfast Colorado Hall ABC7:30 - 8:30 AM Advances in the Multidisciplinary Colorado Hall DE Management of Esophageal Cancer (SAM) 8:30 - 9:30 AM Scientific Session # 3: GI/GU Colorado Hall DE9:30 - 10:15 AM Keynote Speaker: Are Randomized Clinical Colorado Hall DE Trials Still Relevant to Cancer Care 2017? Walter J. Curran MD, FACR - Emory University/ Winship Cancer Institute 10:15 - 10:30 AM Break in Exhibit Hall Colorado Hall ABC10:30 - 11:30 AM Scientific Session # 4: HN/Skin Colorado Hall DE11:30 - 12:30 PM Scientific Session # 5: Translational/QOL/Misc Colorado Hall DE12:45 - 2:15 PM Case-Based Tumor Board: Rectal Cancer *(SAM) Colorado Hall F4:00 - 5:30PM ViewRay, Inc. Industry Symposium Colorado Hall DE This activity is not part of the official ARS scientific program.

6:00 - 9:00 PM President’s Dinner (Invitation Only)

Tuesday, May 9, 20177:00 - 7:30 AM Continental Breakfast Colorado Hall ABC7:30 - 8:00 AM Business Meeting Colorado Hall DE8:00 - 8:30 AM Presidential Lecture: Presidential Session: Brad Ludden, Colorado Hall DE First Descents 8:30 - 9:30 AM Scientific Session # 6: Young Oncologist Essay Session Colorado Hall DE9:30 - 9:45 AM Break in Exhibit Hall Colorado Hall ABC9:45 - 10:30 AM Keynote Lecture: Immunotherapy for Cancer: Beyond Colorado Hall DE Checkpoints - Crystal L. Mackall, MD - Stanford Medicine 10:30 - 11:30 AM Pancreatic Cancer Debate: Is Radiation Needed? (SAM) Colorado Hall DE11:30- 12:30 PM Scientific Session # 7: Mets/Peds/CNS Colorado Hall DE

*Registration and payment required for this session. Space is limited.**Registration and payment required for guests.

Faculty & Moderators

16

Matthew C. Abramowitz, MDUniversity of Miami, Miami, FL

James P. Allison, PhDMD Anderson Cancer Center, Houston, TX

Fariba Asrari, MDJohns Hopkins University, Lutherville, MD

Beth M. Beadle, MD, PhDStanford University, Stanford, CA

Jonathan J. Beitler, MD, MBA, FACRWinship Cancer Institute of Emory University, Atlanta, GA

Jeffrey D. Bradley, MDWashington University School of Medicine, St Louis, MO

Thomas A. Buchholz, MDMD Anderson Cancer Center, Houston, TX

Mark K. Buyyounouski, MD, MSStanford University, Stanford, CA

Daniel T. Chang, MDStanford University, Stanford, CA

George Chang, MD, MS, FACS, FASCRSMD Anderson Cancer Center, Houston, TX

Steve Chmura, MD, PhDUniversity of Chicago, Chicago, IL

Jay S. Cooper, MDMaimonides Cancer Center, Brooklyn, NY

James D. Cox, MDMD Anderson Cancer Center, Houston, TX

Walter J. Curran, MD, FACRWinship Cancer Institute of Emory University, Atlanta, GA

Prajnan Das, MD, MS, MPHMD Anderson Cancer Center, Houston, TX

Neil Desai, MDUniversity of Texas Southwestern, Dallas, TX

Theodore L. DeWeese, MDJohns Hopkins University, Baltimore, MD

Jennifer R. Diamond, MDUniversity of Colorado Cancer Center, Aurora, CO

Frederick M. Dirbas, MDStanford University, Stanford, CA

Anthony Elias, MDUniversity of Colorado, Aurora, CO

Gary M. Freedman, MDUniversity of Pennsylvania, Philadelphia, PA

Michael Gibson, MD, PhDUniversity Hospitals Cleveland Medical Center, Cleveland, OH

Karyn Goodman, MDUniversity of Colorado, Denver, VO, CO

Bruce G. Haffty, MDRutgers Cancer Institute of New Jersey, New Brunswick, NJ

Joseph Herman, MDMD Anderson Cancer Center, Houston, TX

Richard T. Hoppe, MDStanford Cancer Institute, Stanford, CA

Kathleen J. Horst, MDStanford University, Stanford, CA

Charles C. Hsu, MD, PhDUniversity of Arizona Cancer Center, Tucson, AZ

Jerry Jaboin, MD, PhDOregon Health & Science University, Portland, OR

Candice A. Johnstone, MD, MPHMedical College of Wisconsin, Milwaukee, WI

Brian Kavanagh, MD, MPH, FASTROUniversity of Colorado, Aurora, CO

Elizabeth Kidd, MDStanford University, Stanford, CA

Michael Kim, MDMD Anderson Cancer Center, Houston, TX

Eugene J. Koay, MD, PhDMD Anderson Cancer Center, Houston, TX

Ritsuko U. Komaki, MDMD Anderson Cancer Center, Houston, TX

Andre Konski, MD, MBA, MA, FACRUniversity of Pennsylvania, West Chester, PA

Quynh-Thu Le, MD, FACR, FASTROStanford University, Stanford, CA

Steven H. Lin, MDMD Anderson Cancer Center, Houston, TX

Brad Ludden,First Descents, Kalispell, MT

Join Y. Luh, MD, FACPOregon Health & Science University, Portland, OR

Jason Luke, MD, FACPUniversity of Chicago, Chicago, IL

Crystal L. Mackall, MDStanford University, Palo Alto, CA

Harvey Mamon, MD, PhDBrigham and Women’s Hospital, Boston, MD

Susan McGovern, MD, PhDMD Anderson Cancer Center, Houston, TX

Reza J. Mehran, MDMD Anderson Cancer Center, Houston, TX

Wells Messersmith, MDUniversity of Colorado Cancer Center, Aurora, CO

Van Morris, MDMD Anderson Cancer Center, Houston, TX

Benjamin Movsas, MDHenry Ford Hospital, Detroit, MI

Amber Orman, MDMoffitt Cancer Center, Tampa, FL

Mark Pegram, MDStanford University, Stanford, CA

David Raben, MDUniversity of Colorado Cancer Center, Aurora, CO

Kristin Redmond, MD, MPHJohns Hopkins University, Baltimore, MD

Jared R. Robbins, MDMedical College of Wisconsin, Milwaukee, WI

Kenneth B. Roberts, MDYale University School of Medicine, New Haven, CT

Kenneth E. Rosenzweig, MDIcahn School of Medicine at Mount Sinai, New York, NY

Howard Sandler, MDCedars-Sinai Medical Center, Los Angeles, CA

Steven Schild, MDMayo Clinic Arizona, Phoenix, AZ

Farzan Siddiqui, MDHenry Ford Hospital, Detroit, MI

Elin R. Sigurdson, MD, PhDFox Chase Cancer Center, Philadelphia, PA

Charles B. Simone, MDUniversity of Maryland Medical Center, Baltimore, MD

Heath Skinner, MD, PhDMD Anderson Cancer Center, Houston, TX

Ben J. Slotman, MD, PhDVU University Medical Center, Amsterdam, Netherlands

Scott Soltys, MDStanford University, Stanford, CA

Michael C. Stauder, MDMD Anderson Cancer Center, Houston, TX

Kevin L. Stephans, MDCleveland Clinic, Cleveland, OH

Vinita Takiar, MD, PhDUniversity of Cincinnati, Cincinnati, OH

Mediget Teshome, MDMD Anderson Cancer Center, Houston, TX

Wade L. Thorstad, MDWashington University Medical Center, St Louis, MO

Phuoc Tran, MD, PhDJohns Hopkins Medicine, Baltimore, MD

Christina Tsien, MDWashington University School of Medicine, St. Louis, MO

Richard Tuli, MD, PhDCedars-Sinai Medical Center, Los Angeles, CA

Akila N. Viswanathan, MD, MPH, MScJohns Hopkins Medicine, Baltimore, MD

Amanda Walker, MDOffice of Hematology and Oncology Products, US Food and Drug Administration, Silver Spring, MD

Wendy A. Woodward, MDMD Anderson Cancer Center, Houston, TX

Jean L. Wright, MDJohn Hopkins Univerisity, Washington, DC

Sue S. Yom, MD, PhDUniversity of California, San Francisco, San Francisco, CA

James B. Yu, MD, MHSYale School of Medicine, New Haven, CT

Jing Zeng, MDUniversity of Washington, Seattle, WA

Lei Zheng, MD, PhDJohns Hopkins University, Baltimore, MD

17

Disclosure Listing

Name Company Received Role Meeting RoleBayer Consulting Fee ConsultantVarian Consulting Fee ConsultantAmgen Consulting Fee Advisory Committee

Bristol Meyers-Squibb RoyaltyNo current relationship. One time payment of royalties from patent of which I was an inventor.

Jounce Therapeutics Ownership Interest Advisory CommitteeKite Ownership Interest Advisory Committee

Merck Royalty paymentI have no relationship. Merck licensed a patent of which I was an inventor.

Neon Ownership Interest Advisory CommitteeVarian Medical Systems Research Research supportViewRay, Inc Ownership Interest Stock ownershipBrainLab Honoraria Speaking/TeachingElekta Honoraria Speaking/Teaching

George Chang Johnson and Johnson Consulting Fee Consultant FacultyThomas Galloway UpToDate Royalty Program Committee

Bristol-Myers Squibb Consulting Fee ConsultantBristol-Myers Squibb Honoraria Speaking/TeachingMedImmune/AstraZeneca Research ResearchMerck Consulting Fee ConsultantNCCN Research ResearchNCI Research Research

Lauren Henke ViewRay, Inc. Research Speaking/Teaching Abstract PresenterVarian Medical Systems Honoraria Speaking/TeachingMcKesson Honoraria Speaking/Teaching

AMGEN GrantResearch Agreement to perform long-term follow up on patients enrolled in past clinical trials

BMS Travel Expenses ConsultantRedHill Grant Principal InvestigatorVarian Grant Master Research AgreementElekta Inc. Research Independent ContractorHitachi Chemical Inc. Research Independent ContractorAbbVie Research Clinical Trial Support to InstitutionAmgen Consulting Fee ConsultantArray Consulting Fee ConsultantAstraZeneca Consulting Fee ConsultantBeneVir Consulting Fee ConsultantBoston BioMedical Research Clinical Trial Support to InstitutionBristol-Myers Squibb Research Clinical Trial Support to InstitutionBristol-Myers Squibb Consulting Fee ConsultantCelldex Research Clinical Trial Support to InstitutionCheckMate Consulting Fee ConsultantCorvus Research Clinical Trial Support to InstitutionDelcath Research Clinical Trial Support to InstitutionEMD Serono Consulting Fee ConsultantFive Prime Research Clinical Trial Support to InstitutionGenentech Research Clinical Trial Support to InstitutionGilead Consulting Fee ConsultantImmunocore Research Clinical Trial Support to InstitutionIncyte Research Clinical Trial Support to InstitutionMacrogenics Research Clinical Trial Support to InstitutionMedImmune Research Clinical Trial Support to InstitutionMerck Research Clinical Trial Support to InstitutionMerck non-paid ConsultantNovartis Research Clinical Trial Support to InstitutionNovartis Consulting Fee ConsultantPharmacyclics Research Clinical Trial Support to InstitutionTesaro Research Clinical Trial Support to InstitutionPhilips, Inc Research InvestigatorVarian, Inc Research Investigator

Kristin Redmond Elekta AB Research Member of industry sponsored research consortium FacultyJared Robbins Elekta Sponsored Travel to Symposium Speaking/Teaching Faculty

Dendreon Consulting Fee Advisory CommitteeFerring Consulting Fee Advisory CommitteeJanssen Consulting Fee ConsultantAmerican College of Radiology Honoraria ConsultantPhilips Medical Research Our department receives research funding from Philips Medical

Varian Medical Systems ResearchOur department receives research funding from Varian Medical Systems Inc.

Wayne State University Honoraria Speaking/TeachingVarian medical systems Honoraria Responsible for research of dept; speaker at conferenceViewRay Honoraria Speaker at conferenceAstellas Research ResearchAstellas N/A Advisory CommitteeDendreon N/A Advisory CommitteeGenomeDx N/A Advisory Committee

Christina Tsien Merck Honoraria Speaking/Teaching FacultyAkila Viswanathan Augmenix Consultant fees Consultant Program CommitteeJames Yu 21st Century Oncology Research gift to my institution PI-Research gift to my institution Faculty

Michael Gibson

Matthew Abramowitz Faculty

Jason Luke

Benjamin Movsas

Eric Chang

Daniel Chang

James Allison Faculty

Ben Slotman

Phouc Tran

Quynh-Thu Le

Steven Lin

Andre Konski

Howard Sandler

Farzan Siddiqui

Faculty

Faculty

Program Committee

Faculty

Program Committee

Faculty and Program Committee

Faculty

Faculty

Faculty and Program Committee

Faculty

Faculty

Program Committee

The following presenters, faculty, or planning committee members have disclosed the listed financial relationships with commercial interests associated with their participation at the 99th Annual ARS Meeting. Only those that provided information indicating they have a financial relationship with a proprietary entity producing health care goods or services, with the exemption of non-profit or government organizations and non-health care related companies, are listed.

18

Scientific Program

Saturday, May 6, 2017 12:00 - 1:00 PM Resident Lunch: Donald Ross Room History of Radiation Therapy at the Penrose Cancer Hospital James D. Cox, MD, MD Anderson Cancer Center

1:00 - 3:00 PM EduCase SBRT eContouring Symposium Colorado Hall DEThe EduCase tool is used by professional radiation oncology societies as a part of special courses offered to teach segmentation skills. Featured contouring exercises and didactic cases discussions will include:

Session 01 - CNS: Moderator: Scott Soltys, MD, Stanford University Spine - Kristin J. Redmond, MD, MPH, Johns Hopkins University Brain - Christina I. Tsien, MD, Washington University School of Medicine Session 02 - Hepatobiliary: Moderator: Kevin L. Stephans, MD, Cleveland Clinic Pancreas - Richard Tuli, MD, PhD, Cedars-Sinai Medical Center Liver - Eugene J. Koay, MD, PhD, MD Anderson Cancer Center

The contouring workshops are aimed at junior clinical or radiation oncologists who want to improve their contouring skills or at more senior specialists who want to refresh and validate their knowledge and skills in this field.

Workshop participants will be assigned and complete a series contouring exercises prior to each session where the presenting faculty will be able to compare participant’s structures and evaluate contouring performance and display metric evaluation. Instructions and access permissions will be email to registered participants 3 weeks before workshop.

3:15 - 5:30 PM Presidential Categorical Course - Clinical Trials (SAM) Colorado Hall DE

Session Chair: Ben J. Slotman, MD, PhD, VU University Medical Center

Speakers: Amanda Walker, MD, Office of Hematology and Oncology Products, US Food and Drug Administration Karyn Goodman, MD, University of Colorado Jeffrey D. Bradley, MD, Washington University School of Medicine Thomas A. Buchholz, MD, MD Anderson Cancer Center Howard Sandler, MD, Cedars-Sinai Medical Center

At the conclusion of this session, participants will be able to: 1. Provide a comprehensive review of current clinical trials related to each disease site with a focus on multimodality therapy. Each presenter is considered a National expert in their respective sites.2. Review the role of immunotherapy and radiation therapy for each disease site.3. Provide a detailed review of how modern radiation techniques allow for better integration of targeted therapies and immunotherapy.

5:15 - 6:15 PM Opening Reception in Exhibit Hall Colorado Hall ABC Join us for the opening Exhibit and Welcome Reception, take time to network and meet your colleagues.

SATU

RD

AY

SUN

DA

YM

ON

DA

YTU

ESD

AY

19

Scientific Program

6:15 - 7:00 PM Poster Walk Colorado Hall ABC Poster Chair: Farzan Siddiqui, MD, Henry Ford Hospital

Poster Guides: GI - Jared R. Robbins, MD, Medical College of Wisconsin & Elin R. Sigurdson, MD, PhD, Fox Chase Cancer Center Breast - Bruce G. Haffty, MD, Rutgers Cancer Institute of New Jersey Gyn - Fariba Asrari, MD, Johns Hopkins University H/N - Kenneth E. Rosenzweig, MD, Icahn School of Medicine at Mount Sinai & Farzan Siddiqui, MD, Henry Ford Hospital GU - Matthew C. Abramowitz, MD, University of Miami & Phuoc Tran, MD, PhD, Johns Hopkins Medicine Basic Science - Theodore L. DeWeese, MD, Johns Hopkins University & Wendy A. Woodward, MD, MD Anderson Cancer Center Lymphoma - Neil Desai, MD, & University of Texas Southwestern & Richard T. Hoppe, MD, Stanford Cancer Institute Thoracic/Lung - Charles C. Hsu, MD, PhD, University of Arizona Cancer Center & Charles B. Simone, MD, University of Maryland Medical Center Pediatric - Susan McGovern, MD, PhD, MD Anderson Cancer Center & Kenneth B. Roberts, MD, Yale University School of Medicine Palliative Care/QOL - Candice A. Johnstone, MD, MPH, Medical College of Wisconsin & Amber Orman, MD, Moffitt Cancer Center CNS - Steven Schild, MD, Mayo Clinic Arizona & James B. Yu, MD, MHS, Yale School of Medicine

Sunday, May 7, 2017 7:00 - 7:30 AM Continental Breakfast Colorado Hall ABC

7:30 - 8:30 AM Updates in the Management of Cervical Cancer (SAM) Colorado Hall DE Session Chair: Akila N. Viswanathan, MD, MPH, MSc, Johns Hopkins Medicine

Image Guided Brachytherapy - Akila N. Viswanathan, MD, MPH, MSc, Johns Hopkins Medicine IMRT - Elizabeth Kidd, MD, Stanford University Immunotherapy - Jennifer R. Diamond, MD, University of Colorado Cancer Center

8:30 - 9:30 AM Janeway Lecturer Colorado Hall DE Immune Blockade in Cancer Therapy: New Insights and Opportunities James P. Allison, PhD, MD Anderson Cancer Center Introduction by Ritsuko U. Komaki, MD, MD Anderson Cancer Center

9:30 - 10:30 AM Scientific Session # 1: Breast /Gyn Colorado Hall DE Moderators: Jean L. Wright, MD, John Hopkins University & Akila N. Viswanathan, MD, MPH, MSc, Johns Hopkins Medicine

S001: REGIONAL NODAL IRRADIATION IN ELDERLY NODE POSITIVE WOMEN: A PATTERNS OF CARE STUDY ON CHANGES IN UTILIZATION OVER A DECADE - Jason K Molitoris, MD, PhD¹, Tejan Diwanji, MD¹, James W Snider, MD¹, Emily C Bellavance, MD², Susan B Kesmodel, MD², Paula Rosenblatt, MD³, Katherine Tkaczuk, MD³, Soren M Bentzen, PhD⁴, Randi J Cohen, MD², Elizabeth M Nichols, MD⁴, Sally B Cheston⁴, Steven J Feigenberg, MD⁴; ¹University of Maryland Medical Center, ²Dept of Surgical Oncology, University of Maryland School of Medicine, ³Dept of Medical Oncology, University of Maryland School of Medicine, ⁴Dept of Radiation Oncology, University of Maryland School of Medicine

SATU

RD

AY

SUN

DA

YM

ON

DA

YTU

ESD

AY

Scientific Program

20

SATU

RD

AY

SUN

DA

YM

ON

DA

YTU

ESD

AY

S002: POPULATION-BASED ANALYSIS OF THE EFFECT OF MARGIN STATUS ON 10-YEAR LOCAL RECURRENCE AND BREAST CANCER-SPECIFIC SURVIVAL IN WOMEN TREATED WITH BREAST-CONSERVING THERAPY - Susan A Tyler, MD, MSc, FRCPC¹, Pauline Truong, MD, FRCPC¹, Mary Lesperance, PhD², Alan Nichol, MD, CCFP, FRCPC¹, Chris Baliski, MD, FRCSC, FACS³, Rebecca Warburton, MD, FRCSC⁴, Scott Tyldesley, MD, MPA, ABR, FRCPC¹; ¹British Columbia Cancer Agency, Department of Radiation Oncology, ²Department of Mathematics and Statistics, University of Victoria, ³British Columbia Cancer Agency, Department of Surgical Oncology, ⁴University of British Columbia, Department of Surgery

S003: CURATIVE-INTENT TREATMENT FOR NEWLY DIAGNOSED BREAST CANCER WITH LIMITED METASTATIC DISEASE TO THE STERNUM OR MEDIASTINUM. - Kaitlin M Christopherson, MD, Xiudong Lei, PhD, Carlos H Barcenas, MD, MSc, Thomas A Buchholz, MD, Karen Hoffman, MD, Henry M Kuerer, MD, Simona F Shaitelman, MD, George H Perkins, MD, Grace L Smith, MD, Michael C Stauder, MD, Eric A Strom, MD, Welela Tereffe, MD, Wendy A Woodward, MD, PhD, Benjamin D Smith, MD; The University of Texas MD Anderson Cancer Center

S004: HYPOFRACTIONATED RADIATION THERAPY AFTER BREAST CONSERVATION SURGERY FOR DUCTAL CARCINOMA IN SITU - Dennis P Chan, BA, John W Lee, MD, Rahul J Kumar, MD; California Pacific Medical Center

S005: LONG-TERM TOXICITY AND COSMETIC OUTCOMES IN PATIENTS TREATED WITH APBI VIA MULTI-CATHETER INTERSTITIAL HDR BRACHYTHERAPY (ISI) - Prashant Gabani, MD, Maria Thomas, MD, PhD, Jacqueline Zoberi, PhD, Laura Ochoa, RN, PhD, Melissa Matesa, RN, Imran Zoberi, MD; Washington University in Saint Louis

S006: USING QUANTITATIVE 3D METRICS OF BREAST COSMESIS TO COMPARE FRACTIONATION REGIMENS FOR WHOLE BREAST IRRADIATION - Jay P Reddy, MD, PhD¹, Xiudon Lei¹, Prithvi Patil², Krista M Nicklaus³, Michelle C Fingeret¹, Simona F Shaitelman¹, Kelly K Hunt¹, Thomas A Buchholz¹, Fatima Merchant², Mia K Markey³, Benjamin D Smith¹; ¹MD Anderson Cancer Center, ²University of Houston, ³University of Texas

S007: BRACHYTHERAPY IMPROVES SURVIVAL IN PATIENTS FROM A LARGE NATIONAL DATABASE WITH STAGE III ENDOMETRIAL CANCER WITH CERVICAL INVOLVEMENT - Brian S Bingham, BS¹, Andrew Orton, MD², Jessica Huang, PhD², Greg Stoddard, MS, PhD², David Gaffney, MD, PhD², Matthew Poppe, MD²; ¹Vanderbilt University School of Medicine, ²University of Utah School of Medicine

10:30 - 10:45 AM Break in Exhibit Hall Colorado Hall ABC

10:45 - 12:00 PM Scientific Session # 2: Lung/Lymphoma Colorado Hall DEModerators: Jeffrey D. Bradley, MD, Washington University School of Medicine & Ben J. Slotman, MD, PhD, VU University Medical Center

S008: STEREOTACTIC BODY RADIOTHERAPY FOR LARGE (>=5 CM) NON-SMALL CELL LUNG CANCER - Vivek Verma¹, Valerie Shostrom¹, Charles Simone²; ¹University of Nebraska Medical Center, ²University of Pennsylvania

S009: IN SILICO TRIAL OF MR-GUIDED MID-TREATMENT ADAPTIVE PLANNING FOR HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY IN CENTRALLY LOCATED THORACIC TUMORS. - Lauren E Henke, MD, Rojano Kashani, PhD, Daniel Przybysz, MD, Jessica Hilliard, Austen Curcuru, Olga L Green, PhD, Jeffrey D Bradley, MD, Clifford G Robinson, MD; Washington University School of Medicine

Scientific Program

21

SATU

RD

AY

SUN

DA

YM

ON

DA

YTU

ESD

AY

S010: STEREOTACTIC BODY RADIOTHERAPY (SBRT) FOR OPERABLE VS. MEDICALLY INOPERABLE STAGE I NON-SMALL CELL LUNG CANCER: LONG-TERM FIVE-YEAR OUTCOMES AND AN ASSESSMENT BY FRACTIONATION REGIMEN, TUMOR SIZE, AND TUMOR LOCATION - Caitlin A Schonewolf¹, Marina Heskel¹, Abigail Doucette¹, Sunil Singhal¹, Eric P Xanthopoulos², Michael N Corradetti³, Melissa Frick¹, Joseph S Friedberg⁴, Taine T Pechet¹, John P Christodouleas¹, William Levin¹, Kieth A Cengel¹, Abigail T Berman¹, Stephen M Hahn⁵, John C Kucharczuk¹, Ramesh Rengan⁶, Charles B Simone¹; ¹Hospital of the University of Pennsylvania, ²Columbia University Medical Center, ³Duke University School of Medicine, ⁴University of Maryland Medical Center, ⁵University of Texas MD Anderson Cancer Center, ⁶University of Washington Medical Center

S011: DOES INSURANCE STATUS IMPACT SURVIVAL OUTCOMES IN PATIENTS WITH STAGE III NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH CURATIVE INTENT? - Stephanie R Rice, MD, Melissa Vyfhuis, MD, PhD, Bhooshan Neha, MD, PhD, Martin J Edelman, MD, Whitney Burrows, MD, Elizabeth M Nichols, MD, Mohan Suntharalingam, MD, MBA, James Donahue, MD, Shamus Carr, MD, Friedberg Joseph, MD, Shahed N Badiyan, MD, Josephine Feliciano, MD, Steven J Feigenberg, MD, Pranshu Mohindra, MD; University of Maryland Medical Center

S012: CIRCULATING TUMOR DNA DETECTS RESIDUAL DISEASE AND ANTICIPATES TUMOR PROGRESSION EARLIER THAN CT IMAGING - Aadel A Chaudhuri, MD, PhD, Jacob J Chabon, BS, Alexander F Lovejoy, PhD, Aaron M Newman, PhD, Henning Stehr, PhD, Tej D Azad, BS, Li Zhou, MS, Chih Long Liu, PhD, Florian Scherer, MD, David M Kurtz, MD, Mohammad S Esfahani, PhD, Carmen Say, BS, Justin N Carter, BS, David Merriott, BS, Jonathan Dudley, MD, Michael S Binkley, MD, Leslie Modlin, MD, Sukhmani K Padda, MD, Michael Gensheimer, MD, Robert B West, MD, PhD, Joseph B Shrager, MD, Joel W Neal, MD, PhD, Heather A Wakelee, MD, Billy, Jr. W Loo, MD, PhD, Ash A Alizadeh, MD, PhD, Maximilian Diehn, MD, PhD; Stanford Cancer Institute

S013: DOSIMETRIC ANALYSIS OF TREATING MALIGNANT PLEURAL MESOTHELIOMA USING VOLUMETRIC MODULATED ARC THERAPY - Marcher R Thompson, MD, Vishruta A Dumane, PhD, Kenneth E Rosenzweig, MD; The Mount Sinai Hospital

S014: LONG-TERM RESULTS OF A TRIAL OF CONCURRENT CHEMOTHERAPY AND ESCALATING DOSES OF RADIATION FOR UNRESECTABLE NON-SMALL CELL LUNG CANCER: NCCTG N0028 (ALLIANCE) - Helen Ross, MD¹, Steven Schild, MD¹, Shauna Hillman², Angelina Tan², William McGinnis, MD³, Yolanda Garces, MD⁴, David Graham, MD⁵, Alex Adjei, MD⁴, James Jett, MD⁴; ¹Mayo Clinic Arizona, ²Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, ³University of Iowa, ⁴Mayo Clinic, Rochester MN, ⁵Carolinas Medical Center, Levine Cancer Institute

S015: LOCAL CONTROL IS NOT DEPENDENT ON LENGTH OF TREATMENT FOR 5 FRACTION REGIMENS IN LUNG STEREOTACTIC BODY RADIOTHERAPY (SBRT) - Sana Rehman, Michael Roach, Anupama Chundury, Daniel Mullen, Todd DeWees, Jeffrey Bradley, Clifford Robinson; Washington University in St. Louis

S016: ERLOTINIB MAY ENHANCE RADIATION EFFECTS IN PATIENTS WITH STAGE III NON-SMALL-CELL LUNG CANCER - Ritsuko Komaki, Professor, Pamela K Allen, Principal, Statistical, Analyst, Xiong Wei, Data, Manager, George R Blumenschein, Professor, Michael O’Reilly, Professor, Xi Ming Tant, Sr, Research, Scientist, J J Lee, Professor, James Welsh, Professor, Ignacio I Wistuba, Professor, Diane D Liu, Principal, Statistical, Analyst, Meyn E Raymond, Professor, Waun K Hong, Professor; The University of Texas MD Anderson Cancer Center

12:00 - 1:00 PM Oligometastatic and Immunotherapy Panel (SAM) Colorado Hall DE

Scientific Program

22

SATU

RD

AY

SUN

DA

YM

ON

DA

YTU

ESD

AY

Session Chair: Steve Chmura, MD, PhD, University of Chicago

Speakers: Steve Chmura, MD, PhD, University of Chicago; Jason Luke, MD, FACP, University of Chicago; & Lei Zheng, MD, PhD, Johns Hopkins University

1:15 - 2:45 PM Case-Based Tumor Board: Breast Cancer *(SAM) Colorado Hall FThe Breast Cancer Case Based Tumor Board will focus on the multidisciplinary care of patients with breast cancer. Cases will be discussed by a team of breast cancer specialists, including breast surgeons, medical oncologists, and radiation oncologists. This session is open to anyone interested in the management of breast cancer.

Session Chair: Kathleen J. Horst, MD, Stanford UniversitySpeakers: Frederick M. Dirbas, MD, Stanford University; Anthony Elias, MD, University of Colorado; Gary M. Freedman, MD, University of Pennsylvania; Mark Pegram, MD, Stanford University; Michael C. Stauder, MD, MD Anderson Cancer Center; Mediget Teshome, MD, MD Anderson Cancer Center & Erqi Liu, MD, Stanford University

Management of Breast Cancer from a Medical Oncologist Viewpoint - Mark Pegram, MD & Anthony Elias, MDManagement of Breast Cancer from a Surgical Oncologist Viewpoint - Frederick Dirbas, MD & Mediget Teshome, MDManagement of Breast Cancer from a Radiation Oncologist Viewpoint - Gary Freedman, MD & Michael Stauder, MD

At the conclusion of this session, participants will be able to: 1. Care for patients with breast cancer in a multidisciplinary setting.2. Discuss the management of patients treated with neoadjuvant chemotherapy3. Review the role of surgery and radiotherapy in the management of patients with lymph node involvement.

5:30 - 7:00PM Resident vs. Faculty Medical Jeopardy Colorado Hall DE Session Chair: Join Y. Luh, MD, FACP, Oregon Health & Science University Emcee: David Raben, MD, University of Colorado Cancer Center

Come see some of the brightest residents from around the country in a friendly, but highly competitive, game of Jeopardy. The competition tests the medical knowledge of resident teams, each representing a region in the United States. The winning team is granted a place in ARS history.

7:30 - 9:30 PM ARS Social Event at the Cheyenne Lodge** Join us for a fun night at the Broadmoor’s Cheyenne Lodge! Shuttles will leave from Broadmoor South at 7:20pm. Attendees and guests must wear their meeting badge in order to board the shuttle.

Monday, May 8, 2017 7:00 - 7:30 AM Continental Breakfast Colorado Hall ABC

7:30 - 8:30 AM Advances in the Multidisciplinary Management of Colorado Hall DE Esophageal Cancer (SAM)

The session will begin with a brief overview on the state of the art in the multidisciplinary management of esophageal cancer, to be followed with talks

Scientific Program

23

SATU

RD

AY

SUN

DA

YM

ON

DA

YTU

ESD

AY

from three experts on the current advances in surgical, radiation and systemic therapies.

Session Chair: Steven H. Lin, MD, MD Anderson Cancer Center

Current State of the Art in Multimodality Management of Esophageal Cancer - Steven H. Lin, MD, MD Anderson Cancer CenterSurgical Advances to Improve Outcomes in Esophageal Cancer - Reza J. Mehran, MD, MD Anderson Cancer CenterOptimizing Radiation Therapy for Esophageal Cancer - Jing Zeng, MD, University of WashingtonImprovements and Opportunities in Systemic Therapy for Esophageal Cancer - Michael Gibson, MD, PhD, University Hospitals Cleveland Medical CenterQuestion & Answers – All Faculty

At the conclusion of this session, participants will be able to: 1. Critically appraise the evidence supporting the current standard of care in the treatment of esophageal cancer2. Assessing the advances in surgical and radiation technologies on improving outcomes in esophageal cancer3. Understanding the critical areas of unmet needs and development in systemic therapies for advanced disease

8:30 - 9:30 AM Scientific Session # 3: GI/GU Colorado Hall DEModerators: Mark K. Buyyounouski, MD, MS, Stanford University & Andre Konski, MD, MBA, MA, FACR, University of Pennsylvania

S017: PATTERN OF FAILURE, MARGIN STATUS AND ADJUVANT THERAPY IN PANCREATIC CANCER: IMPACT ON SURVIVAL - Arsen Osipov, MD¹, Joanne K Rutgers, MD¹, Deepti Dhall, MD¹, Jason Naziri¹, Shefali Chopra, MD², Quanlin Li¹, Nicholas Nissen, MD¹, Andrew Hendifar, MD¹, Richard Tuli, MD, PhD¹; ¹Cedars-Sinai Medical Center, ²University of Southern California

S018: A PROSPECTIVE TRIAL OF INTENSITY-MODULATED RADIATION THERAPY (IMRT) INCORPORATING A SIMULTANEOUS INTEGRATED BOOST FOR PROSTATE CANCER: LONG-TERM OUTCOMES COMPARED WITH STANDARD IMAGE-GUIDED IMRT - Steven E Schild, MD, Michael H Schild, DO, William W Wong, MD, Sujay A Vora, MD, Sameer R Keole, MD, Carlos E Vargas, MD, Thomas B Daniels, MD, Gary A Ezzell, PhD, Ba E Nguyen, MD, Michael C Roarke, MD; Mayo Clinic

S019: LYMPHOCYTE-SPARING EFFECT OF PROTON THERAPY IN PATIENTS WITH ESOPHAGEAL CANCER - Penny Fang, MD, Yutaka Shiraishi, Wen Jiang, MD, PhD, Juhee Song, PhD, Brian P Hobbs, PhD, Steven Lin, MD, PhD; University of Texas MD Anderson Cancer Center

S020: ARE EARLY STAGE ANAL CANCER PATIENTS OVERTREATED WITH CHEMORADIOTHERAPY? - Thomas M Churilla, MD, Lyudmila DeMora, MS, Elizabeth Handorf, PhD, Nicholas Zaorsky, MD, Yanqun Dong, MD, PhD, Crystal Denlinger, MD, Elin Sigurdson, MD, Joshua Meyer, MD; Fox Chase Cancer Center

S021: A PHASE 2 RANDOMIZED DOUBLE BLINDED STUDY EVALUATING THE EFFICACY OF CURCUMIN WITH PRE-OPERATIVE CHEMORADIATION FOR RECTAL CANCER - Jillian R Gunther, MD, PhD, Awalpreet S Chadha, MD, Peiying Yang, PhD, Mark F Munsell, MS, Prajnan Das, MD, Marc E Delclos, MD, Wai C Foo, MD, Harmeet Kaur, MD, Marilyn Clemons, RN, Geena G Mathew, MS, George J Chang, MD, Miguel A Rodriguez-Bigas, MD, John M Skibber, MD, Manoop Bhutani, MD, Gottumukkala S Raju, MD, Cathy Eng, MD, Sushovan Guha, MD, Sunil Krishnan, MD; The University of Texas MD Anderson Cancer Center

Scientific Program

24

SATU

RD

AY

SUN

DA

YM

ON

DA

YTU

ESD

AY

S022: CAN IMAGING-BASED BIOMARKERS OF PANCREATIC CANCER BE USED TO SELECT PATIENTS FOR DOSE-ESCALATED RADIOTHERAPY? - Shalini Moningi, MD¹, Ahmed Amer¹, Lauren Colbert¹, Yeonju Lee¹, Robert Wolff¹, Gauri Varadhachary¹, Prajnan Das¹, Joseph M Herman¹, Cullen Taniguchi¹, Jason B Fleming¹, Matthew H Katz¹, Christopher Crane², Ott Le¹, Priya Bhosale¹, Eric Tamm¹, Eugene J Koay¹; ¹MD Anderson Cancer Center, ²Memorial Sloan Kettering

S023: COLORECTAL CANCER SCREENING AMONG MEN WITH NEWLY DIAGNOSED PROSTATE CANCER - Brooke K Leachman, MD, Lawrence J Scharf, MD, Mark L Sobczak, MD; Fox Chase Cancer Center

9:30 - 10:15 AM Keynote Speaker Colorado Hall DEAre Randomized Clinical Trials Still Relevant to Cancer Care in 2017?Walter J. Curran MD, FACR, Emory University and Winship Cancer Institute Introduction by Benjamin Movsas, MD, Henry Ford Hospital

10:15 - 10:30 AM Break in Exhibit Hall Colorado Hall ABC

10:30 - 11:30 AM Scientific Session # 4: HN/Skin Colorado Hall DEModerators: Jonathan J. Beitler, MD, MBA, FACR, Winship Cancer Institute of Emory University & Jay S. Cooper, MD, Maimonides Cancer Center

S024: EXTRACAPSULAR EXTENSION IS ASSOCIATED WITH WORSE DISTANT CONTROL AND PROGRESSION-FREE SURVIVAL IN PATIENTS WITH LYMPH NODE-POSITIVE HUMAN PAPILLOMAVIRUS-RELATED OROPHARYNGEAL CARCINOMA - Adam Bossert, BS, Jeffrey Shevach, BA, Richard Bakst, MD, Jerry Liu, MD, Krzysztof Misiukiewicz, MD, Jessica Beyda, MD, Brett Miles, MD, DDS, Eric Genden, MD, Marshall R Posner, MD, Vishal Gupta, MD; Icahn School of Medicine at Mount Sinai

S025: POSTOPERATIVE RADIATION THERAPY FOR ADENOID CYSTIC CARCINOMA OF THE SALIVARY GLAND: PATTERNS OF CARE AND SURVIVAL OUTCOMES - Anna Lee, MD, MPH¹, Babak Givi, MD², Dylan Roden², Virginia W Osborn, MD¹, Elizabeth Garay¹, David Schwartz¹, Kwang Choi¹, David Schreiber¹; ¹Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, New York, ²Department of Otolaryngology, New York School of Medicine, New York, New York

S026: PHASE II TRIAL OF ELECTIVE NODAL DOSE 36 GY FOR ADVANCED HEAD AND NECK CANCER - Patrick D Maguire, MD¹, Charles R Neal, MD¹, Ashley Adams, BS², Stuart M Hardy, MD³, Andrew M Schreiber, MD⁴; ¹Coastal Carolina Radiation Oncology, ²New Hanover Regional Medical Center, SEAHEC, ³Wilmington Ear, Nose, & Throat, ⁴New Hanover Regional Medical Center, Medical Oncology

S027: HYPOFRACTIONATED RADIOTHERAPY IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL AMONG PATIENTS WITH EARLY-STAGE GLOTTIC CANCER - Trevor J Bledsoe, MD¹, Henry S Park, MD, MPH¹, John M Stahl, MD¹, Wendell G Yarbrough, MD, MMHC, FACS², Barbara A Burtness, MD³, Roy H Decker, MD, PhD¹, Zain A Husain, MD¹; ¹Department of Therapeutic Radiology, Yale School of Medicine, ²Department of Surgery, Otolaryngology, Yale School of Medicine, ³Department of Medicine, Yale School of Medicine

S028: MEASUREMENT OF CIRCULATING TUMORS CELLS IN SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AND PATIENT OUTCOMES - Tiffany Morgan¹, Xu Wang, PhD¹, Ximei Qian, PhD¹, Shuming Nie, PhD², Dong M Shin, MD¹, Jonathan J Beitler, MD¹; ¹Winship Cancer Institute of Emory University, ²Georgia Tech University

Scientific Program

25

SATU

RD

AY

SUN

DA

YM

ON

DA

YTU

ESD

AY

S029: DEVELOPMENT OF AN IMMUNE-ASSOCIATED MOLECULAR SIGNATURE PREDICTING MELANOMA SURVIVAL - Goran Micevic¹, Viswanathan Muthusamy¹, Gulietta Pupo², Richard Scolyer², Georgina Long², Marcus Bosenberg¹; ¹Yale School of Medicine, ²Melanoma Institute of Australia

S030: EARLY SRS OF MELANOMA BRAIN METASTASES IN PATIENTS TREATED WITH IPILIMUMAB - Yi An, MD¹, Wen Jiang, MD, PhD², Veronica L Chiang, MD¹, Jing Li, MD, PhD²; ¹Yale University School of Medicine, ²The University of Texas MD Anderson Cancer Center

11:30 - 12:30 PM Scientific Session # 5: Translational, Quality of Life and Outcomes Colorado Hall DE Research

Moderators: Heath Skinner, MD, PhD, MD Anderson Cancer Center & Vinita Takiar, MD, PhD, University of Cincinnati

S031: RACIAL DISPARITIES IN PROTON BEAM THERAPY UTILIZATION IN THE UNITED STATES - Arya Amini, Paul Maroni, Elizabeth Kessler, E. David Crawford, Thomas Flaig, Brandon Bernard, David Raben, Elaine Lam, Thomas Pugh; University of Colorado School of Medicine

S032: INVESTIGATING CDKN2A COPY NUMBER LOSS IN HPV- AND HPV+ HEAD AND NECK CANCER: A DEMONSTRATION OF INTEGRATED GENOMIC AND CLINICAL ANALYSES USING TCGA - William S Chen, BS, Ranjit S Bindra, MD, PhD, Allen Mo, BS, Thomas Hayman, MD, Zain Husain, MD, Joseph N Contessa, MD, PhD, James B Yu, MD, MHS; Yale School of Medicine

S033: QUESTIONING THE ROLE OF INFLAMMATION IN TUMOR-INDUCED FATIGUE - Aaron Grossberg, MD, PhD1, Elisabeth Vichaya, PhD1, Diana Christian, BS1, Jessica M Molkentine, BS1, Cobi J Heijnen, PhD1, Annemieke Kavelaars, PhD1, Daniel Vermeer, BS2, John H Lee, MD2, Robert Dantzer, DVM, PhD1; 1The University of Texas MD Anderson Cancer Center, 2Cancer Biology Research Center, Sanford Research

S034: DOES A COMMUNITY CANCER CENTER ONE-DAY PROSTATE CANCER MULTI-DISCIPLINARY CLINIC RESULT IN A CHANGE IN TREATMENT RECOMMENDATION? - Taylor Cushman, MS¹, Joseph W Mashni², Terence Roberts, MD³, Rachit Kumar, MD³; ¹University of Arizona College of Medicine-Phoenix, ²Division of Urology, Banner MD Anderson Cancer Center, ³Division of Radiation Oncology, Banner MD Anderson Cancer Center

S035: EVALUATING THE ROLE OF SMAD 4 AS A PREDICTOR OF CLINICAL OUTCOMES IN PANCREATIC CANCER - John David, MD, Arsen Osipov, MD, Gillian Gresham, MS, Shant Thomassian, BS, Andrew Hendifar, MD, Richard Tuli, MD, PhD; Cedars Sinai Medical Center

S036: RESIDENT SUPERVISION IN CONTOURING, TREATMENT PLANNING, AND PLAN EVALUATION: A NATIONWIDE SURVEY OF RADIATION ONCOLOGY RESIDENTS. - Mani Akhtari, MD¹, Aakash Batra¹, Vivek Verma, MD², Lee R Wiederhold, MD, PhD²; ¹UTMB Galveston, ²University of Nebraska

S037: AN OVERVIEW OF DISPARITIES RESEARCH IN ACCESS TO RADIATION ONCOLOGY CARE - Shearwood McClelland III, MD¹, Curtiland Deville, MD², Charles R Thomas Jr, MD¹, Jerry J Jaboin, MD, PhD¹; ¹Department of Radiation Medicine, Oregon Health & Science University, Portland, OR, ²Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins Hospital, Baltimore, MD

S038: DO RACE OR INCOME INFLUENCE QUALITY OF LIFE (QOL) OR SURVIVAL (OS) AFTER LUNG STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN STAGE I NON-SMALL CELL LUNG CANCER? A PROSPECTIVE STUDY - Avielle Movsas, BA, Sean Vance, MD, Karine Al-Feghali, MD, Andrew Taylor, MA, Manpreet Kaur, Christine Neslund-Dudas, PhD, Indrin Chetty, PhD, Michael Simoff, MD, Benjamin Movsas, MD, Munther Ajlouni, MD; Henry Ford Health System

Scientific Program

26

SATU

RD

AY

SUN

DA

YM

ON

DA

YTU

ESD

AY

12:45 - 2:15 PM Case-Based Tumor Board: Rectal Cancer *(SAM) Colorado Hall FThis session will discuss the multidisciplinary management of rectal cancer, with case presentations and expert viewpoints from medical oncology, surgical oncology, and radiation oncology. This session will be of interest to residents, fellows, and attending physicians, in medical oncology, surgical oncology, radiation oncology, and radiology.

Session Chair and Moderator: Prajnan Das, MD, MS, MPH, MD Anderson Cancer CenterPanelists: George Chang, MD, MS, FACS, FASCRS, MD Anderson Cancer Center; Harvey Mamon, MD, PhD, Brigham and Women’s Hospital; & Van Morris, MD, MD Anderson Cancer Center

Case Presentations #1-4 - Prajnan Das, MD, MS, MPH, MD Anderson Cancer CenterDiscussions, Cases #1-4 - George Chang, MD, MS, FACS, FASCRS, MD Anderson Cancer Center; Harvey Mamon, MD, PhD, Brigham and Women’s Hospital; & Van Morris, MD, MD Anderson Cancer CenterQuestion & Answers – All Faculty

At the conclusion of this session, participants will be able to: 1. Understand current standards and recent advances in the role of systemic therapy for rectal cancer.2. Understand current standards and recent advances in the role of surgery for rectal cancer.3. Understand current standards and recent advances in the role of radiation oncology for rectal cancer.

6:00 - 9:00 PM President’s Dinner (Invitation Only)

Tuesday, May 9, 2017 7:00 - 7:30 AM Continental Breakfast Colorado Hall ABC

7:30 - 8:00 AM Business Meeting Colorado Hall DE

8:00 - 8:30 AM Presidential Session Colorado Hall DE Session Introduction by Quynh-Thu Le, MD, FACR, FASTRO, Stanford University Speaker Introduction by Beth M. Beadle, MD, PhD, Stanford University Speaker: Brad Ludden, Founder of First Descents

8:30 - 9:30 AM Scientific Session # 6: Young Oncologist Essay Session Colorado Hall DEModerators: Beth M. Beadle, MD, PhD, Stanford University & Wade L. Thorstad, MD, Washington University Medical Center

S039: RECURSIVE PARTITIONING ANALYSIS IS PREDICTIVE OF OVERALL SURVIVAL FOR PATIENTS UNDERGOING SPINE STEREOTACTIC RADIOSURGERY - Ehsan H Balagamwala, Jacob A Miller, BS, Chandana A Reddy, MS, Lilyana Angelov, MD, John H Suh, MD, Mohammad B Tariq, BS, Erin S Murphy, MD, Kailin Yang, PhD, Toufik Djemil, PhD, Anthony Magnelli, MS, Alireza M Mohammadi, MD, Sherry Soeder, CNP, Samuel T Chao, MD; Cleveland Clinic

S040: THE RISK OF LEVEL IB NODAL INVOLVEMENT IN OROPHARYNX CANCER: GUIDANCE FOR SUBMANDIBULAR GLAND SPARING IRRADIATION - Nicholas C Lee, BSc¹, Jacqueline R Kelly, MD, MSc¹, Henry S Park, MD, MPH¹, Wendell G Yarbrough, MD, MMHC, FACS², Barbara A Burtness, MD³, Zain A Husain, MD¹; ¹Department of Therapeutic Radiology, Yale School of

27

Scientific Program

Medicine, ²Section of Otolaryngology, Department of Surgery, Yale School of Medicine, ³Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine

S041: ONLINE PALLIATIVE CARE PATIENT EDUCATION RESOURCES: DO THEY MEET NATIONAL HEALTH LITERACY RECOMMENDATIONS? - Arpan V Prabhu, BS¹, Tudor Crihalmeanu, BA², David R Hansberry, MD, PhD³, Nitin Agarwal, MD⁴, David A Clump, MD, PhD¹, Dwight E Heron, MD, MBA, FACRO, FACR¹, Sushil Beriwal, MD¹; ¹University of Pittsburgh Cancer Institute, ²West Virginia University School of Medicine, ³Thomas Jefferson University Hospitals, ⁴University of Pittsburgh Medical Center

S042: INVASIVE LOBULAR CARCINOMA PREDICTS FOR AN INCREASED LIKELIHOOD OF SURGICAL UPSTAGING REQUIRING POST-MASTECTOMY RADIATION THERAPY - Renae D Van Wyhe, MBA¹, Simona F Shaitelman, MD¹, Abigail S Caudle, MD², Karen E Hoffman, MD¹, George H Perkins, MD¹, Welela Tereffe, MD, MPH¹, Benjamin D Smith, MD¹, Eric A Strom, MD¹, Thomas A Buchholz, MD¹, Wendy A Woodward, MD, PhD³, Michael C Stauder, MD¹; ¹Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, ²Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, ³MD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic

S043: HETEROGENEITY IN TREATMENT RESPONSE OF SPINE METASTASES TO SPINE STEREOTACTIC RADIOSURGERY WITHIN “RADIOSENSITIVE” SUBTYPES - Vincent Bernard¹, Andrew J Bishop, MD¹, Pamela K Allen, PhD¹, Behrang Amini, MD, PhD¹, Xin A Wang¹, Jing Li, PhD¹, Claudio E Tatsui, MD¹, Laurence D Rhines, MD¹, Paul D Brown, MD², Amol J Ghia¹; ¹MD Anderson Cancer Center, ²Mayo Clinic

9:30 - 9:45 AM Break in Exhibit Hall Colorado Hall ABC

9:45 - 10:30 AM Keynote Lecture Colorado Hall DE Immunotherapy for Cancer: Beyond Checkpoints Crystal L. Mackall, MD, Stanford University Introduction by Quynh-Thu Le, MD, FACR, FASTRO, Stanford University

10:30 - 11:30 AM Pancreatic Cancer Debate: Is Radiation Needed? (SAM) Colorado Hall DESession Chairs: Daniel T. Chang, MD, Stanford University & Joseph Herman, MD, MSc, MD Anderson Cancer Center

Radiotherapy for Locally Advanced Disease - Daniel T. Chang, MD, Stanford UniversityAdjuvant Therapy for Pancreatic Cancer – Does Radiation Still Have a Role? - Wells Messersmith, MD, University of Colorado Cancer CenterRadiation and Immunotherapy - Lei Zheng, MD, PhD, Johns Hopkins University,Management of Borderline Resectable Disease - Michael Kim, Michael Kim, MD, MD Anderson Cancer CenterDicussion & Debate – All Faculty

11:30- 12:30 PM Scientific Session # 7: Metastic Disease, Pediatrics, and CNS Colorado Hall DEModerators: Jerry Jaboin, MD, PhD, Oregon Health & Science University & Brian Kavanagh, MD, MPH, FASTRO, University of Colorado

S044: A SINGLE INSTITUTION EXPERIENCE WITH THE UTILITY OF BRAIN SIMULTANEOUS 18F-FDG-PET/MRI TO DIFFERENTIATE TUMOR RECURRENCE FROM RADIATION NECROSIS - Comron J Hassanzadeh, BS¹, Anupama Chundury, MD², Jackson Rowe³, Michelle Miller-Thomas, MD⁴, Christina Tsien, MD²; ¹University of Missouri Kansas City, ²Department of Radiation Oncology,Washington University School of Medicine, ³Saint Louis University School of Medicine, ⁴Division of Neuroradiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine

SATU

RD

AY

SUN

DA

YM

ON

DA

YTU

ESD

AY

28

Scientific Program

S045: LOSS OF H3K27 TRIMETHYLATION IS PROGNOSTIC FOR WORSE OUTCOMES FROM MENINGIOMA - David R Raleigh, MD, PhD¹, Areli K Cuevas-Ocampo¹, Ashley Wu¹, Bryan Tomlin, PhD², Joshua Menke, MD, PhD¹, Gerald Reis, MD¹, Tarik Tihan, MD, PhD¹, Arie Perry, MD¹, Melike Pekmezci, MD¹; ¹UCSF, ²California State University Channel Islands

S046: LONG-TERM OUTCOME AND TOXICITY OF STEREOTACTIC ABLATIVE BODY RADIOTHERAPY (SABR) FOR LIVER METASTASES FROM SOLID TUMORS - Yi Lu, MD, PhD¹, Chad Tang, MD, MS², Zhongxing Liao, MD², Melenda Jeter, MD, MPH², Stephen Hahn, MD², Prajnan Das, MD, MPH², Eugene Koay, MD, PhD², Joseph Herman, MD², Quynh-Nhu Nguyen, MD²; ¹Ningbo medical center Lihuili Eastern Hospital, ²The University of Texas MD Anderson Cancer Center

S047: CNS RELAPSE OF RHABDOMYOSARCOMA - Brian De, BA, Leonard H Wexler, MD, Kim Kramer, MD, Suzanne L Wolden, MD; Memorial Sloan Kettering Cancer Center

S048: RE-IRRADIATION FOR RECURRENT PEDIATRIC CNS MALIGNANCIES: A MULTI-INSTITUTIONAL RETROSPECTIVE REVIEW - Avani D Rao, MD¹, Arif Rashid, MD¹, Qinyu Chen, MHS¹, Rosangela C Villar, MD², Daria Kobyzeva³, Kristina Nilsson, MD, PhD⁴, Karin Dieckmann, MD⁵, Alexey Nechesnyuk, MD³, Ralph Ermoian, MD⁶, Sara Alcorn, MD¹, Shannon M MacDonald, MD⁷, Matthew M Ladra, MD¹, Eric C Ford, PhD⁶, Brian A Winey, PhD⁷, Maria Luisa S Figueiredo, MD⁸, Stephanie A Terezakis, MD¹, Michael J Chen, MD⁸; ¹Johns Hopkins School of Medicine, ²Department of Radiation Oncology, Centro Infantil Boldrini, ³Federal Scientific Clinical Centre of Children’s Hematology, Oncology and Immunology, ⁴Uppsala University Hospital, ⁵Universität Klinik Für Strahlentherapie und Strahlenbiologie, ⁶University of Washington, ⁷Massachusetts General Hospital, ⁸Grupo de Apoio ao Adolescente e à Criança com Câncer

S049: INTERNAL VALIDATION OF THE PROGNOSTIC INDEX FOR SPINE METASTASIS (PRISM) FOR STRATIFYING SURVIVAL IN PATIENTS TREATED WITH SPINAL STEREOTACTIC RADIOSURGERY - Garrett Jensen1, Chad Tang2, Kenneth R Hess², Andrew J Bishop², Hubert Y Pan², Jing Li², James N Yang², Nizar M Tannir², Behrang Amini², Claudio Tatsui², Laurence Rhines², Paul D Brown², Amol Ghia²; ¹Baylor College of Medicine, ²MD Anderson

SATU

RD

AY

SUN

DA

YM

ON

DA

YTU

ESD

AY

Poster Listing

29

P001: DMAPT INHIBITS NF-KAPPA B ACTIVITY AND INCREASES SENSITIVITY OF PROSTATE CANCER CELLS TO X-RAYS IN VITRO AND IN TUMOR XENOGRAFTS IN VIVO - Marc S Mendonca, PhD1, William T Turchan, BS1, Melanie E Day, BS¹, Christopher N Watson, MD¹, Neil C Estabrook, MD¹, Helen Chin-Sinex, BS¹, Jeremy B Shapiro, BS¹, Imade Imasuen, BA¹, Gabriel Rangel, BS¹, David P Gilley, PhD², Nazmul Huda, PhD¹, Peter A Crooks, PhD³, Ronald H Shapiro, MD¹; ¹Indiana University School of Medicine, ²South Dakota School of Mines and Technology, ³University of Arkansas for Medical Sciences

P002: DIFFERENTIAL EXPRESSION OF MICRORNA BETWEEN STANDARD CONVENTIONAL DOSE VERSUS ABLATIVE DOSE RADIATION IN COL-ORECTAL CANCER - Shushan Rana, MD, Cristina Espinosa, PhD, Charles Thomas, MD, Sudarshan Anand, PhD; Oregon Health & Science University

P003: DELIVERY OF ULTRA-RAPID FLASH RADIATION THERAPY AND DEMONSTRATION OF NORMAL TISSUE SPARING AFTER ABDOMINAL IR-RADIATION OF MICE - Billy W Loo, MD, PhD, Emil Schuler, PhD, Frederick M Lartey, PhD, Marjan Rafat, PhD, Gregory J King, PhD, Stefania Trovati, PhD, Albert C Koong, MD, PhD, Peter G Maxim, PhD; Stanford University

P006: CARE PATHWAY ALTERNATIVES FOR EARLY STAGE BREAST CANCER RADIOTHERAPY: A NATIONAL CANCER DATABASE ANALYSIS - Ehsan H Balagamwala, MD¹, Bindu V Manyam, MD¹, C M Leyrer, MD¹, Naveen Karthik¹, Timothy Smile, BS¹, Rahul D Tendulkar, MD¹, Sheen Cherian, MD¹, Diane Radford, MD¹, Zahraa AlHilli, MD¹, Frank Vicini, MD², Chirag S Shah, MD¹; 1Cleveland Clinic, ²21st Century Oncology/Michigan Healthcare Professionals

P007: TREATMENT CHANGES ASSOCIATED WITH PRE-OPERATIVE AXILLARY ULTRASOUND ON BREAST CANCER. - Andrew Dockter, BS¹, Kyle Rus-so, MD², Abe E Sahmoun, PhD¹; ¹University of North Dakota School of Medicine and Health Sciences, ²Bismarck Cancer Center

P008: IMPACT OF RADIOTHERAPY ON LYMPHOTROPIC INVASIVE MICROPAPILLARY CARCINOMA OF THE BREAST: AN ANALYSIS FROM THE NATIONAL CANCER DATA BASE - Gary D Lewis¹, Yan Xing², Tejal Patel², Mary R Schwartz², Albert C Chen³, Andrew M Farach², Sandra S Hatch¹, E B Butler², Jenny C Chang², Bin S Teh²; ¹University of Texas Medical Branch at Galveston, ²Houston Methodist Hospital, ³Baylor College of Medicine

P009: ASSESSMENT OF LUMPECTOMY CAVITY RADIOTHERAPY BOOST VOLUME WITH REPEAT CT SIMULATION - Aman Saini, BBA¹, Steven Sckol-nik, MD², Anushka Patel, MD²; ¹Midwestern University, ²Arizona Center for Cancer Care

P010: CONCURRENT CHEMOTHERAPY WITH ADJUVANT RADIATION FOR BREAST CANCER AFTER INCOMPLETE RESPONSE TO NEOADJUVANT CHEMOTHERAPY: SAFETY AND OUTCOMES - Thomas D Mullen, MD, PhD, Amy E Chang, MD, Hannah M Linden, MD, Janice N Kim, MD; University of Washington

P011: POSTMASTECTOMY RADIOTHERAPY FOR T3N0 BREAST CANCERS: A NATIONAL CANCER DATABASE ANALYSIS - Samual R Francis, MD, Jona-than Frandsen, MD, Kristine Kokeny, MD, David Gaffney, MD, PhD, Matthew Poppe, MD; Huntsman Cancer Hospital

P012: BREAST CANCER PATIENTS WITH COLLAGEN VASCULAR DISEASE MAY BE UNDERTREATED WITH RADIATION DESPITE LOW RATES OF TOXICITY - Michael J LaRiviere, MD, Jennifer Vogel, MD, Peter Gabriel, MD, MSE, Gary M Freedman, MD; University of Pennsylvania

P013: OUTCOMES AFTER SALVAGE MASTECTOMY FOR AN IPSILATERAL BREAST TUMOR RECURRENCE AFTER BREAST CONSERVATION THERAPY - Talha Shaikh, Tianyu Li, Vladimir Avkshtol, Stephanie Weiss, Elin Sigurdson, Shelly Hayes, Penny Anderson; Fox Chase Cancer Center

P014: POPULATION-BASED ANALYSIS OF RADIATION OMISSION IN ELDERLY BREAST CANCER PATIENTS - A S Wallace, K S Keene, C P Williams, M Pisu, E E Partridge, G B Rocque; University of Alabama at Birmingham

P015: RADIOTHERAPY AFTER SKIN-SPARING MASTECTOMY AND PLACEMENT OF A TISSUE EXPANDER: EFFECTIVENESS OF A COORDINATED, MULTIDISCIPLINARY APPROACH - Zeina Ayoub, MD¹, Eric A Strom, MD¹, Valentina Ovalle, MD², George H Perkins, MD¹, Wendy A Woodward, MR, PhD¹, Welela Tereffe, MD, MPH¹, Benjamin D Smith, MD¹, Simona F Shaitelman, MD¹, Michael C Stauder, MD¹, Karen E Hoffman, MD¹, Sarah M DeSny-der, MD¹, Patrick B Garvey, MD¹, Marc W Clemens, MD¹, Carlos H Barcenas, MS, MSc¹, Henry M Kuerer, MD, PhD¹, Steven Kronowitz, MD¹; ¹University of Texas MD Anderson Cancer Center, ²Clinica IRAM

P016: A PHASE I/II TRIAL OF 5-FRACTION STEREOTACTIC RADIOSURGERY WITH 5MM MARGINS WITH CONCURRENT AND ADJUVANT TEMO-ZOLOMIDE IN NEWLY DIAGNOSED SUPRATENTORIAL GLIOBLASTOMA: QUALITY OF LIFE AND UPDATED OUTCOMES - Erqi Pollom, Sara Dudley, Melissa Azoulay, Dylann Fujimoto, Jacob Wynne, Kira Seiger, Leslie M Modlin, Lisa Rose Jacobs, Laurie Tupper, Iris Gibbs, Steven Hancock, Gordon Li, Steven Chang, John Adler, Griffith Harsh, Ciara Harraher, Seema Nagpal, Reena Thomas, Clara Choi, Scott Soltys; Stanford

P017: MANAGEMENT OF CHORDOMA AND CHONDROSARCOMA WITH FRACTIONATED STEREOTACTIC RADIOTHERAPY - Harish N Vasudevan, PhD, David R Raleigh, MD, PhD, Julian Johnson, MD, Adam A Garsa, MD, Philip V Theodosopoulos, MD, Manish K Aghi, MD, PhD, Christopher Ames, MD, Michael W McDermott, MD, Igor J Barani, MD, Steve E Braunstein, MD, PhD; University of California San Francisco

P018: THE ROLE OF OREXIN IN BRAIN RADIATION-INDUCED FATIGUE - Aaron J Grossberg, MD, PhD, Die Zhang, PhD, Wei Zhou, PhD, Connie C Weng, PhD, Phillip Gross, BS, Elisabeth G Vichaya, PhD, Robert Dantzer, DVM, PhD, David R Grosshans, MD, PhD; The University of Texas MD Anderson Cancer Center

P019: LINAC-BASED STEREOTACTIC RADIOSURGERY AND FRACTIONATED STEREOTACTIC RADIOTHERAPY FOR BRAIN METASTASES FROM SAR-COMA - Andrew Keller, BS¹, Michael Yu, MD², Arash O Naghavi, MD², Timothy J Robinson, MD, PhD², Siriporn Sarangkasiri, MS², Arnold B Etame, MD, PhD², Peter A Johnstone, MD², Kamran A Ahmed, MD²; ¹University of Central Florida College of Medicine, ²H. Lee Moffitt Cancer Center Department of Radiation Oncology

P020: EVALUATION OF NONCOPLANAR/COPLANAR VERSUS COPLANAR ARCS IN FRACTIONATED STEREOTACTIC RADIOTHERAPY OF PITUITARY ADENOMAS. - Susan A Tyler, MD, MSc, FRCPC, Sergei Zavgorodni, PhD, Abraham Alexander, MD, FRCPC, Isabelle Vallieres, MD, MSc, FRCPC; British Columbia Cancer Agency, Department of Radiation Oncology

P021: CENTRAL NERVOUS SYSTEM EDEMA, BRAIN INVASION AND PRIOR RADIOTHERAPY ARE NEGATIVE PREDICTIVE FACTORS FOR SYMPTOM-ATIC IMPROVEMENT FOLLOWING SURGERY FOR MENINGIOMA - Ashley Wu, BA, Steve E Braunstein, MD, Michael A Garcia, Philip V Theodosopoulos, MD, Penny K Sneed, MD, Arie Perry, MD, Michael W McDermott, MD, David R Raleigh, MD, PhD; University of California San Francisco

P024: REDUCED-VOLUME RADIOTHERAPY FOR PATIENTS WITH LOCALIZED INTRACRANIAL NONGERMINOMA GERM CELL TUMORS - Brian De, Oren Cahlon, Ira J Dunkel, Kevin C De Braganca, Suzanne L Wolden; Memorial Sloan Kettering Cancer Center

P025: PREDICTORS OF SURVIVAL IN INTRAHEPATIC CHOLANGIOCARCINOMA TREATED WITH STEREOTACTIC BODY RADIATION THERAPY: A NATIONAL CANCER DATABASE STUDY - Michael W Straza, MD, PhD, Thomas C Gamblin, MD, Jared R Robbins, MD; Medical College of Wisconsin

P026: ALKALINE PHOSPHATASE AT THE START OF LIVER DIRECTED RADIATION IS A PREDICTOR OF LONG TERM LIVER VOLUME CHANGES - Konstantin A Kovtun, MD¹, Nicholas Giacolone, MD¹, Sagar Patel, MD¹, Jennifer Y Wo, MD², John A Wolfgang, PhD², Theodore S Hong, MD2; ¹Harvard Radiation Oncology Program, Massachusetts General Hospital, ²Department of Radiation Oncology, Massachusetts General Hospital

30

P027: EVALUATING TREATMENT PATTERNS FOR SMALL CELL CARCINOMA OF THE COLON USING THE NATIONAL CANCER DATABASE - Sadhana Balasubramanyam¹, Barrett P O’Donnell¹, Michelle S Ludwig, MD, MPH, PhD², Benjamin L Musher, MD², Pavan M Jhaveri, MD²; ¹John P. and Katherine G. McGovern Medical School, ²Baylor College of Medicine

P028: PATIENT RETENTION AFTER INITIAL CONSULTATION RESULTS IN EXTENDED SURVIVAL IN PANCREATIC CANCER - Lauren M Rosati, BS¹, Deirdre Torto, MHA², Amy Hacker-Prietz, MS, PAC¹, Amol K Narang, MD¹, Elliot K Fishman, MD³, Ralph H Hruban, MD⁴, Alison P Klein, MHS, PhD⁵, Elizabeth M Jaffee, MD⁵, Matthew J Weiss, MD⁶, Christopher L Wolfgang, MD, PhD⁶, Daniel A Laheru, MD⁵, Joseph M Herman, MD, MSc¹; ¹Department of Radiation Oncology & Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, ²The Johns Hopkins Sidney Kimmel Comprehen-sive Cancer Center, ³Department of Radiology, The Johns Hopkins University School of Medicine, ⁴Department of Pathology, The Johns Hopkins University School of Medicine, ⁵Department of Oncology, The Johns Hopkins University School of Medicine, ⁶Department of Surgery, The Johns Hopkins University School of Medicine

P029: PENCIL BEAM SCANNING PROTON TREATMENT OF MOBILE DISTAL ESOPHAGEAL CARCINOMAS PRODUCE SIMILAR PATHOLOGIC COMPLETE RESPONSE RATES AS PHOTON TREATMENT - Rosanna H Yeung, Meghan W Macomber, Jing Zeng, Smith Apisarnthanarax; University of Washington

P031: EARLY CLINICAL EXPERIENCE IN HIGH DOSE MRI GUIDED ADAPTIVE RADIATION THERAPY FOR INOPERABLE PANCREATIC CANCER - Ashley Weiner¹, Ishita Chen¹, Austen Curcuru¹, Lauren Henke¹, Olga Green¹, Stephanie Markovina¹, Hiram Gay¹, Cliff Robinson¹, Michael Roach¹, Jeffrey Olsen², Rojano Kashani¹, Parag Parikh¹; ¹Washington University School of Medicine, ²University of Colorado School of Medicine

P032: PREOPERATIVE CHEMORADIATION FOR LOCALLY ADVANCED PANCREATIC CANCER IMPROVES PATHOLOGIC FINDINGS WHEN COM-PARED TO ADJUVANT CHEMORADIATION - Camille Berriochoa, MD¹, May Abdel-Wahab, MD, PhD², C M Leyrer, MD¹, Mohamed Abazeed, MD, PhD¹, Alok Khorana, MD¹, R M Walsh, MD¹, Aryavarta Kumar, MD, PhD³; ¹Cleveland Clinic Foundation, ²International Atomic Energy Agency, ³University Hospi-tals of Case Western Reserve University

P033: DO SOCIODEMOGRAPHIC FACTORS AND COMORBIDITIES SIGNIFICANTLY INFLUENCE OUTCOME IN PROSTATE CANCER PATIENTS TREAT-ED WITH EXTERNAL BEAM RADIATION THERAPY? - Aviva Movsas, Mohamed Elshaikh, MD, Lois Lamerato, PhD, Mei Lu, PhD, Yueren Zhou, PhD, Avielle Movsas, BA, Hans Stricker, MD, Indrin Chetty, PhD, Benjamin Movsas, MD, Farzan Siddiqui, MD, PhD; Henry Ford Health System

P034: EVOLUTION OF BRACHYTHERAPY FOR PROSTATE CANCER - Nicholas G Zaorsky, MD¹, Brian J Davis, MD, PhD², Paul L Nguyen, MD³, Timothy N Showalter, MD⁴, Peter J Hoskin, MD⁵, Yasuo Yoshioka, MD, PhD⁶, Gerard Morton, MD⁷, Eric M Horwitz, MD¹; ¹Fox Chase Cancer Center, ²Mayo Clinic, ³Brigham and Women’s Hospital, Boston, ⁴University of Virginia, ⁵Mount Vernon Cancer Centre, ⁶Osaka University Graduate School of Medicine, ⁷Sunny-brook Health Sciences Centre

P035: STEREOTACTIC BODY RADIATION THERAPY FOR ORGAN-CONFINED PROSTATE CANCER - Richard Shumway, MD, David Grew, MD, Joseph Colasanto, MD, Laura Patrick; Saint Francis Hospital, Hartford, CT

P036: IMPLEMENTATION OF HYPOFRACTIONATED PROSTATE RADIOTHERAPY IN THE UNITED STATES: A NATIONAL CANCER DATABASE ANALY-SIS - William A Stokes, MD, Brian D Kavanagh, MD, MPH, David Raben, MD, Thomas J Pugh, MD; University of Colorado Denver School of Medicine

P037: ACUTE AND LATE TOXICITY REPORT OF POST-PROSTATECTOMY PROTON THERAPY FOR PROSTATE CANCER PATIENTS UNDERGOING AD-JUVANT OR SALVAGE RADIOTHERAPY - Akansha Jain¹, Neha Vapiwala, MD¹, Kristina D Woodhouse, MD¹, Stefan Both, PhD², Peter Gabriel, MD¹, Zelig Tochner, MD¹, Curtiland Deville, MD³; ¹University of Pennsylvania, ²Memorial Sloan Kettering Cancer Center, ³Johns Hopkins University

P038: COMPARISON OF NEOADJUVANT VERSUS CONCURRENT/ADJUVANT INITIATION OF ANDROGEN DEPRIVATION IN MEN WITH HIGH-RISK PROSTATE CANCER RECEIVING DEFINITIVE RADIATION THERAPY - Anna Lee, MD, MPH¹, Daniel J Becker², Ariel J Lederman¹, Virginia W Osborn¹, Meng S Shao¹, Andrew T Wong¹, David Schwartz¹, David Schreiber¹; ¹Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, New York, ²Department of Medicine, NYU School of Medicine, New York, New York

P039: UPDATED ACUTE AND LATE GASTROINTESTINAL AND GENITOURINARY TOXICITY OF DOSE-ESCALATED IMAGE-GUIDED INTENSITY MODULATED RADIATION THERAPY FOR PROSTATE CANCER USING A DAILY WATER-FILLED ENDORECTAL BALLOON - Christopher Montoya, BS¹, Neha Vapiwala, MD², Stefan Both, PhD², Curtiland Deville, MD³; ¹Lewis Katz School of Medicine at Temple University, ²The Hospital of the University of Pennsylvania, ³Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

P040: A PROSPECTIVE PILOT STUDY OF PSA LEVELS DURING POST-OPERATIVE PROSTATE-BED ONLY SALVAGE RADIOTHERAPY AS A PREDICTOR OF TREATMENT RESPONSE - Daniel X Yang, BS¹, Arie P Dosoretz, MD, MBA², James B Yu, MD, MHS¹; ¹Yale School of Medicine, ²21st Century Oncology

P041: EFFECT OF HPV/P16 STATUS ON RESPONSE TO POSTOPERATIVE RADIOTHERAPY (RT) IN SQUAMOUS CELL CARCINOMA OF THE PENIS (PECA) - Zhigang Yuan, MD, PhD, Jasreman Dhillon, MD, Arash Naghavi, MD, MS, Dominic Tang, MD, Kamran Ahmed, MD, Philippe E Spiess, MD, Anna Giuliano, PhD, Peter Johnstone, MD; Moffitt Cancer Center

P042: THE IMPACT OF ADJUVANT MANAGEMENT ON SURVIVAL ENDPOINTS IN WOMEN WITH STAGE I TYPE II ENDOMETRIAL CARCINOMA. - Gregory M Hermann, MD, MPH, Ahmed M Ibrahim, BS, Andrew Taylor, MS, Hesham E Tanbour, BS, Mohamed A Elshaikh; Henry Ford Hospital

P043: ENDOMETRIAL CANCER: FIGO STAGE I OUTCOMES AND TRENDS IN RADIATION TREATMENT MODALITY. - Akkamma Ravi, MD¹, Simcha Pollack, PhD²; ¹Weill Cornell Medical College, New York Presbyterian Hospital Queens, ²St. Johns University

P044: TOXICITY OF POST-OPERATIVE INTENSITY MODULATED RADIATION THERAPY IN PATIENTS WITH CERVICAL CANCER - Jessika A Contre-ras, MD, Anupama Chundury, MD, Amar Srivastava, MD, Julie Schwarz, MD, PhD, Premal Thaker, MD, Kuroki Lindsay, MD, David Mutch, MD, Matthew Powell, MD, Perry Grigsby, MD; Washington University in St. Louis

P046: FACTORS PREDICTIVE OF RECEIVING ADJUVANT RADIOTHERAPY IN HIGH-INTERMEDIATE RISK STAGE I ENDOMETRIAL CANCER - Ariel Pollock¹, Mary McGunigal¹, John T Doucette, PhD², Jerry Liu, MD³, Manjeet Chadha, MD³, Tamara Kalir, MD⁴, Vishal Gupta, MD³; ¹Icahn School of Medicine at Mount Sinai, ²Icahn School of Medicine, Department of Environmental Medicine & Public Health, ³Icahn School of Medicine at Mount Sinai, Department of Radiation Oncology, ⁴Icahn School of Medicine at Mount Sinai, Department of Pathology

P047: WHICH PATIENTS WITH INOPERABLE VULVAR CANCER MAY BENEFIT FROM BRACHYTHERAPY IN ADDITION TO EXTERNAL BEAM RADI-ATION? A SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) ANALYSIS - Yuan J Rao¹, Carissa Hui², Anupama Chundury¹, Julie Schwarz¹, Todd DeWees¹, Matthew Powell¹, David Mutch¹; ¹Washington University in St. Louis, ²St. Louis University School of Medicine

P048: GEOGRAPHIC VARIATION IN INITIAL LARYNGECTOMY FOR LOCALLY ADVANCED LARYNX CANCER - Miriam Lango¹, Steven Zuniga, MD², Thomas Galloway, MD¹, Drew Ridge, MD, PhD¹; ¹Fox Chase Cancer Center, Temple University Health System, ²Temple University School of Medicine

Poster Listing

31

P049: THE PROGNOSTIC IMPACT OF HPV STATUS FOLLOWING TREATMENT FAILURE IN OROPHARYNGEAL CANCER - Richard L Bakst, MD, Eesha Dave, Umut Ozbez, PhD, Vishal Gupta, MD, Brett Miles, MD, Marshall Posner, MD; Mount Sinai

P050: ADJUVANT RADIATION FOR SALIVARY GLAND MALIGNANCIES IS ASSOCIATED WITH IMPROVED SURVIVAL- AN ANALYSIS FROM THE NATIONAL CANCER DATABASE - William W Su, Ryan Rhome, MD, PhD, Umut Ozbek, PhD, Miriam Knoll, MD, Vishal Gupta, MD, Brett A Miles, MD, DDS, Richard L Bakst, MD; Icahn School of Medicine at Mount Sinai

P052: SMALL REDUCTIONS IN DOSE APPEAR EQUALLY EFFECTIVE FOR HPV POSITIVE OROPHARYNGEAL CANCER PATIENTS - Jessica Kennedy, PhD¹, Dawn Gintz, CMD², Kevin Shah¹, Jimmy Caudell, MD, PhD²; ¹University of South Florida, ²Moffitt Cancer Center

P053: PATTERNS OF FAILURE AFTER MULTIMODALITY TREATMENT OF ESTHESIONEUROBLASTOMA: HIGH RISK FOR MENINGEAL FAILURE AMONG PATIENTS WITH DURAL INVASION AT LONG-TERM FOLLOWUP - Yao Yu, MD¹, Ivan H El-Sayed, MD¹, Michael W McDermott, MD¹, Norbert Kased, MD², Christine M Glastonbury, MD¹, Adam A Garsa, MD¹, Sue S Yom, MD, PhD, MAS¹; ¹University of California, San Francisco, ²Scripps

P054: THE IMPACT OF ADJUVANT RADIATION THERAPY FOR MALIGNANT SALIVARY GLAND TUMORS - Meng Shao, MD¹, Joseph Safdieh, MD¹, Babak Givi, MD², Anna Lee, MD¹, Dylan F Roden, MD², Kwang Choi¹, David Schwartz, MD¹, David Schreiber, MD¹; ¹SUNY Downstate, ²NYU

P055: TCIA IMAGING DATABASE FOR HEAD AND NECK SQUAMOUS CELL CARCINOMA PATIENTS TREATED WITH RADIOTHERAPY - Aaron J Grossberg, MD, PhD¹, Abdallah S R Mohamed, MD¹, Sasikarn Chamchod, MD², William Bennett³, Kirk Smith, PhD³, Tracy Nolan, PhD³, Michael Kantor, BS¹, Theodora Browne, BA¹, David I Rosenthal, MD¹, Clifton D Fuller, MD, PhD¹; ¹The University of Texas MD Anderson Cancer Center, ²Chulabhorn Hos-pital, Bangkok, Thailand, ³University of Arkansas for Medical Sciences

P056: A PROPOSED REVISION TO THE KADISH-MORITA STAGING SYSTEM FOR ESTHESIONEUROBLASTOMA - Andrew Orton, MD, Daniel Evans, BS, Dustin Boothe, MD, Shane Lloyd, MD, Greg Stoddard, MStat, MBA, Ying J Hitchcock, MD; University of Utah

P057: ESTHESIONEUROBLASTOMA: EVIDENCE FOR THE ROLE OF ADJUVANT RADIOTHERAPY IN LOCALLY ADVANCED DISEASE - Andrew Orton, Dustin Boothe, Daniel Evans, Shane Lloyd, Marcus Monroe, Randy Jensen, Dennis Shrieve, Ying J Hitchcock; University of Utah

P058: SIDE BY SIDE: COMPARING RECEIPT OF SUPPORTIVE THERAPY FOR HEAD AND NECK CANCER AT AN ADJACENT PRIVATE AND COUN-

TY HOSPITAL - Hayley K Perlow, BS, Raphael Yechieli, MD, Ben Silver, BS, Adam Jaffe, BS, Deukwoo Kwon, PhD, Brian Jimenez, BS, Stuart Samuels, MD, Stephen Ramey, MD; University of Miami

P059: IMPACT OF INCREASING ATLAS SIZE ON ACCURACY OF AN ATLAS-BASED AUTO-SEGMENTATION PROGRAM (ABAS) FOR ORGANS-AT-RISK (OARS) IN HEAD AND NECK (H&N) CANCER PATIENTS. - Steven Gresswell, MD, Paul Renz, DO, Day Werts, PhD, Youssef Arshoun, MD; Allegheny Health Network

P060: SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY OF THE HEAD AND NECK: “LOW-RISK” PROGNOSTIC FACTORS FOR DISEASE CONTROL AND SURVIVAL REMINISCENT OF OROPHARYNGEAL CANCERS - Margaret J Zhou, BS¹, Annemieke Van Zante, MD, PhD², Ann A Lazar, PhD³, Eli R Groppo, MD⁴, Adam A Garsa, MD¹, William R Ryan, MD⁵, Ivan H El-Sayed, MD⁵, David W Eisele, MD⁶, Sue S Yom, MD, PhD, MAS¹; ¹Depart-ment of Radiation Oncology, University of California, San Francisco, ²Department of Pathology, University of California, San Francisco, ³Department of Pre-ventive and Restorative Dental Sciences, University of California, San Francisco, ⁴Sacramento Ear, Nose and Throat, ⁵Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, ⁶Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University

P061: A DOSIMETRIC COMPARISON OF BOLUS ELECTRON CONFORMAL RADIOTHERAPY, ELECTRON THERAPY, AND 3D-CONFORMAL RADIA-TION THERAPY FOR BASAL CELL AND SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK: A SINGLE INSTITUTIONAL EXPERIENCE - Anupa-ma Chundury, MD¹, Jessika Contreras, MD¹, Sarah Bertelsman¹, Christen Elledge, MD², Wade Thorstad, MD¹, Hiram Gay, MD¹, James Kavanaugh, MS¹, Imran Zoberi, MD¹; ¹Washington University School of Medicine, ²John Hopkins University School of Medicine

P062: FRACTIONATION PATTERNS FOR PATIENTS WITH T2N0M0 GLOTTIC CANCER UNDERGOING DEFINITIVE RADIOTHERAPY: A NATIONAL CANCER DATABASE ANALYSIS - William A Stokes, MD, Ryan M Lanning, MD, PhD, Sana D Karam, MD, PhD, David Raben, MD; University of Colorado Denver School of Medicine

P063: BRACHYTHERAPY FOR PREVIOUSLY IRRADIATED HEAD AND NECK CANCER - William Breen; Mayo Medical School

P064: PATTERNS OF CARE IN ADJUVANT THERAPY FOR RESECTED ORAL CAVITY SQUAMOUS CELL CANCER IN THE ELDERLY - Alexander L Chin, MD, MBA¹, Erqi L Pollom, MD, MS¹, Nancy Y Lee, MD², C. Jillian Tsai, MD, PhD²; ¹Department of Radiation Oncology, Stanford Cancer Institute, Stanford, CA, ²Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

P065: SEVERE WEIGHT LOSS DURING, BUT NOT BEFORE, CHEMO-IRRADIATION FOR STAGE III AND IV SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IS ASSOCIATED WITH INCREASED SURVIVAL - Danielle L Tamburrini, DO¹, Casey G Sheck, DO¹, Shawn Shaikh², Mckenzie Montana², Jessica Tyrrell², Michael A Davis, DO¹, Jill Darminio², Gus J Slotman, MD³; ¹Department of Surgery Inspira Health Network Vineland, NJ, ²Inspi-ra Health Network, ³Southern New Jersey Head and Neck Cancer Treatment Network

P066: OUTCOMES AND PATTERNS OF FAILURE OF SARCOMATOID CARCINOMA OF THE LARYNX: THE MAYO CLINIC EXPERIENCE - Elizabeth B Jeans, MAE¹, Mauricio Gamez, MD¹, Michael L Hinni, MD¹, Eric Moore, MD², Geoffrey Young, MD, PhD², Daniel Ma, MD², Lisa McGee, MD¹, Matthew Buras, MS¹, Samir H Patel, MD¹; ¹Mayo Clinic Arizona, ²Mayo Clinic Rochester

P067: SURVIVAL OUTCOMES WITH ADJUVANT CHEMORADIATION VERSUS ADJUVANT RADIATION ALONE FOR ELDERLY PATIENTS WITH RE-SECTED HEAD AND NECK SQUAMOUS CELL CARCINOMA WITH POSITIVE SURGICAL MARGINS OR EXTRA-CAPSULAR EXTENSION - Nicholas J Giacalone, MD¹, Muhammad M Qureshi, MBBS², Kimberly S Mak, MD, MPH², Diana Kirke, MBBS³, Sagar A Patel, MD¹, Bhartesh A Shah, MD², Andrew Salama, MD⁴, Scharukh Jalisi, MD³, Minh Tam Truong, MD²; ¹Harvard Radiation Oncology Program, Boston, MA, ²Department of Radiation Oncology, Boston Medical Center, Boston University School of Medicine, Boston, MA, ³Department of Otolaryngology, Head and Neck Surgery, Boston Medical Cen-ter, Boston University School of Medicine, Boston, MA, ⁴Department of Oral & Maxillofacial Surgery, Boston Medical Center, Boston University Henry M. Goldman School of Dental Medicine, Boston, MA

P069: PROGNOSTIC FACTORS FOR RECURRENCE AND SURVIVAL INDEPENDENT OF THE REVISED AJCC 8TH EDITION STAGING SYSTEM IN PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA - Melody J Xu, Adam A Garsa, Ann Lazar, Sarah T Arron, William R Ryan, Ivan El-Sayed, Alain A Algazi, Jonathan George, Patrick Ha, Sue S Yom; University of California, San Francisco

P070: MALIGNANT GLOSSOPHARYNGEAL NEURALGIA, A PAINFUL SYNCOPE - Christina Binder, Brianna Ketterer; Oregon Health and Science Univer-sity

P071: MANAGEMENT AND SURVIVAL OUTCOMES FOR LYMPH NODE NEGATIVE T3 SQUAMOUS CELL CARCINOMA OF THE GLOTTIC LARYNX - H Ko, S Chen, M Yu, A Wieland, G Hartig, P Harari, M Witek; University of Wisconsin

Poster Listing

32

P072: PROSPECTIVE VALIDATION OF BIOELECTRICAL IMPEDANCE ANALYSIS FOR CLINICALLY APPLICABLE MONITORING OF BODY COMPO-SITION IN HEAD AND NECK CANCER PATIENTS TREATED WITH RADIOTHERAPY - Aaron J Grossberg, MD, PhD¹, Crosby D Rock, BS², Abdallah S R Mohammed, MD¹, Debra Ruzensky, RD¹, Angela Currie, RD¹, Patricia Rosemond, RD¹, Jack Phan, MD, PhD¹, G. Brandon Gunn, MD¹, Steven J Frank, MD¹, William H Morrison, MD¹, Adam S Garden, MD¹, David I Rosenthal, MD¹, Clifton D Fuller, MD, PhD¹; ¹The University of Texas MD Anderson Cancer Cen-ter, ²Texas Tech University Health Sciences Center

P073: MANAGEMENT OF SQUAMOUS CELL CARCINOMA OF THE SCALP WITH BONE INVOLVEMENT. - Mohamed K Abdelhakiem, Jared Robbins, MD, Frank J Wilson, MD; Medical College of Wisconsin

P074: PATIENT-REPORTED QUALITY OF LIFE OUTCOMES AFTER DE-ESCALATED CHEMORADIATION FOR HPV-POSITIVE OROPHARYNGEAL CAR-CINOMA: FINDINGS FROM A PHASE II TRIAL - John V Hegde, MD¹, Narek Shaverdian, MD¹, Megan E Daly, MD², Carol Felix¹, Jordan Garst¹, Jessica Meshman, MD¹, Karen Kelly, MD², Allen M Chen, MD³; ¹University of California, Los Angeles Medical Center, ²University of California, Davis Comprehen-sive Cancer Center, ³University of Kansas Medical Center

P075: THYROID GLAND SPARING RADIOTHERAPY IN THE MANAGEMENT OF HEAD AND NECK CANCER: A SINGLE INSTITUTION PROSPECTIVE APPROACH TO ASSESS FEASIBILITY, SAFETY, AND RESPONSE - Tyler P Robin, MD, PhD, Arya Amini, MD, Nicole Ryan, BS, CMD, Sana D Karam, MD, PhD, David Raben, MD; Department of Radiation Oncology, University of Colorado Cancer Center

P076: SEQUENTIAL BOOST COMPARED WITH SIMULTANEOUS INTEGRATED BOOSTS FOR HPV POSITIVE OROPHARYNGEAL CANCER PATIENTS - Kevin Shah¹, Dawn Gintz, CMD², Jessica Kennedy, PhD¹, Jimmy Caudell, MD, PhD²; ¹University of South Florida, ²Moffitt Cancer Center

P077: HYPOFRACTIONATED RADIATION THERAPY HAS FAVORABLE COSMESIS FOR INDOLENT SKIN CANCERS - Nicholas G Zaorsky, MD, Charles T Lee, Eddie Zhang, MD, Thomas J Galloway, MD; Fox Chase Cancer Center

P078: RADIOTHERAPY FOR PAROTID MALIGNANCIES: PATTERNS OF CARE AND IMPACT ON OVERALL SURVIVAL - Zachary H Hopkins, BS¹, Dustin Boothe, MD², Ying Hitchcock, MD²; ¹University of Utah School of Medicine, ²Hunstsman Cancer Institute

P079: PRACTICE PATTERNS OF THORACIC RADIOTHERAPY FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER: SURVEY OF UNITED STATES AC-ADEMIC THORACIC RADIATION ONCOLOGISTS - Carl M Post, BS¹, Vivek Verma, MD¹, Timur Mitin, MD, PhD², Charles B Simone II, MD³; ¹Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, ²Department of Radiation Medicine, Oregon Health and Science University, Portland, OR, ³Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA

P080: IMMUNE PARAMETERS AS PREDICTORS OF PNEUMONITIS AND SURVIVAL IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER TREATED WITH CHEMORADIATION - Quoc-Anh Ho, BS¹, Lihong Qi, PhD², Shyam S Rao, MD, PhD³, Megan E Daly, MD³; ¹University of California Davis, School of Medicine, ²University of California Davis, Comprehensive Cancer Center, Department of Biostatistics, ³University of California Davis, Comprehen-sive Cancer Center, Department of Radiation Oncology

P081: DEFINITIVE HYPOFRACTIONATED RADIATION IN THE TREATMENT OF CLINICAL N1 NON-SMALL CELL LUNG CANCER (NSCLC) - Colton C Gits, Sana Rehman, MD, Michael C Roach, MD, Christina K Speirs, MD, PhD, Anupama Chundury, MD, Lauren Henke, MD, Daniel Mullen, DDS, Todd DeWees, PhD, Jeffrey D Bradley, MD, Clifford G Robinson, MD; Washington University in St. Louis

P082: BLACK PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (LA- NSCLC) - AN INCLUSIVE MULTI-MODALITY AP-PROACH IS JUSTIFIED - Vyfhuis Melissa, MD, PhD¹, Neha Bhooshan, MD, PhD¹, Jason Molitoris, MD, PhD¹, Martin Edelman, MD¹, Whitney Burrows, MD¹, Elizabeth Nichols, MD¹, Mohan Suntharalingam, MD, MBA¹, James Donahue, MD¹, Carr Shamus, MD¹, Joseph Friedberg, MD1, Shahed Badiyan, MD¹, Josephine Feliciano, MD², Steven Feigenberg, MD¹, Pranshu Mohindra, MD, MBBS¹; ¹UMMC, ²Johns Hopkins Hospital

P083: DIFFERENTIAL COMPLETE PATHOLOGIC RESPONSE BY HISTOLOGY AFTER HIGH DOSE NEOADJUVANT CHEMORADIATION - Tijana Skrep-nik, MD, Sun Yi, MD, Linda Garland, MD, Justin Suszko, MD, Samuel Kim, MD, Charles Hsu, MD, PhD; University of Arizona

P084: STEREOTACTIC ABLATIVE RADIOTHERAPY FOR STAGE I NON-SMALL-CELL LUNG CANCER TUMORS GREATER THAN 5 CM - Eric M Ander-son¹, Akanksha Sharma², Kenneth D Westover², Robert Timmerman², Rie von Eyben¹, Michael F Gensheimer¹, Peter Maxim¹, Bill W Loo¹, Maximilian Diehn¹, David B Shultz³; ¹Stanford University, ²UT Southwestern, ³University of Toronto

P085: TRENDS IN STEREOTACTIC BODY RADIATION THERAPY FOR STAGE I SMALL CELL LUNG CANCER - John M Stahl, MD¹, Christopher D Corso, MD, PhD¹, Vivek Verma, MD², Henry S Park, MD, MPH¹, Sameer K Nath, MD¹, Zain A Husain, MD¹, Charles B Simone, II, MD³, Anthony W Kim, MD⁴, Roy H Decker, MD, PhD¹; ¹Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, ²Department of Radiation Oncology, Uni-versity of Nebraska School of Medicine, Omaha, NE, ³Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴Department of Surgery, Section of Thoracic Surgery, Yale University School of Medicine, New Haven, CT

P086: SUCCESS OF STEREOTACTIC BODY RADIATION THERAPY IN CENTRAL VERSUS PERIPHERAL RETREATMENT OF NON-SMALL CELL LUNG CANCER - Jason Chan, MD, Julian Johnson, MD, Ann Lazar, PhD, Steve Braunstein, MD, PhD, Martina Descovich, PhD, Alexander Gottschalk, MD, PhD, Adam Garsa, MD, Sue Yom, MD, PhD, MAS; University of California San Francisco

P087: THE DOSIMETRIC EFFECTS OF LIMITED ELECTIVE NODAL IRRADIATION IN VOLUMETRIC MODULATED ARC THERAPY TREATMENT PLANNING FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER - Mark C Kenamond, R. A Siochi, PhD, Malcolm D Mattes, MD; West Virginia University

P088: SPLENIC IRRADIATION FOR SPLENOMEGALY: A META-ANALYSIS - Nicholas G Zaorsky, MD, Graeme R Williams, BSE, BA, Stefan K Barta, MD, Nestor F Esnaola, MD, Patricia L Kropf, MD, Shelly B Hayes, MD, Joshua E Meyer, MD; Fox Chase Cancer Center

P089: COMPARISON OF SURVIVAL BY DIFFERENT PALLIATIVE RADIATION THERAPY FRACTIONATION SCHEDULES - Sara A Dudley, Sonya Aggarw-al, Yushen Qian, Aadel Chaudhuri, Kiran Kumar, Daniel T Chang; Stanford Cancer Institute

P090: STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES FROM PRIMARY HEAD AND NECK CARCINOMAS: A RETROSPECTIVE ANALY-SIS - Rajal A Patel, MD, Jonathan Bell, Thomas Kim, MD, Mark Agulnik, MD, James P Chandler, MD, Bharat B Mittal, MD, Tim J Kruser, MD; Northwestern University

P091: STEREOTACTIC BODY RADIATION THERAPY FOR ADRENAL GLAND METASTASES - Kristin A Plichta, MD, PhD, Nathaniel B Camden, BS, Bryan G Allen, MD, PhD, John M Buatti, MD; University of Iowa Hospitals and Clinics

P092: A COMPREHENSIVE ANALYSIS OF CLINICAL TRIALS INCLUDING BOTH RADIATION THERAPY AND IMMUNOTHERAPY. - Dustin Boothe, MD¹, Michael Christensen², Shane Lloyd, MD¹; ¹University of Utah, Department of Radiation Oncology, ²University of Utah, School of Medicine

Poster Listing

33

Poster Listing

P093: PALLIATIVE RADIATION FOR BONE METASTASES FROM HEPATOCELLULAR CARCINOMA: PRACTICE PATTERNS AND THE IMPLICATIONS OF FRACTION SCHEME ON THE AMOUNT OF REMAINING LIFE SPENT RECEIVING TREATMENT - Ryan K Schmid, BS, Abdulrahman Y Hammad, MD, Candice Johnstone, MD, MPH, T C Gamblin, MD, MS, Jared R Robbins, MD; Medical College of Wisconsin

P094: FINANCIAL CONFLICTS OF INTEREST ARE CORRELATED WITH PUBLICATION PRODUCTIVITY AMONG ACADEMIC RADIATION ONCOLO-GISTS - Nicholas G Zaorsky¹, Awad A Ahmed, MD², Clifton D Fuller, MD³, Charles R Thomas, Jr, MD⁴, Emma B Holliday, MD³; ¹Fox Chase Cancer Center, ²University of Miami, ³The University of Texas MD Anderson Cancer Center, ⁴Oregon Health and Science University Knight Cancer Institute

P095: ASSESSING CHANGES IN THE ACTIVITY LEVELS OF BREAST CANCER PATIENTS DURING RADIATION THERAPY - Colin E Champ¹, Nitin Ohri, MD², Matthew Cantor³, Rainer J Klement, PhD⁴, Ryan P Smith¹; ¹Department of Radiation Oncology, University of Pittsburgh Medical Center, ²Department of Radiation Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, ³Koneksa Health Inc, New York City, NY, ⁴Depart-ment of Radiation Oncology, Leopoldina Hospital, Schweinfurt, Germany

P096: DELINEATION OF FIELDS FOR PROPHYLACTIC RADIATION THERAPY TO PREVENT HETEROTOPIC OSSIFICATION SURROUNDING THE SCI-ATIC NERVE - William T Turchan, BS, Neil C Estabrook, MD, Kevin P McMullen, MD; Indiana University School of MedicineP097: TWO-AND-A-HALF YEAR CLINICAL EXPERIENCE WITH MAGNETIC RESONANCE IMAGE GUIDED RADIATION THERAPY - Benjamin W Fisch-er-Valuck, MD¹, Lauren Henke, MD¹, Rojano Kashani, PhD¹, Olga Green, PhD¹, Jeffrey Olsen, MD², Parag Parikh, MD¹, Cliff Robinson, MD¹, Jeff Bradley, MD¹, Maria Thomas, MD, PhD¹, Michael Roach, MD¹, Imran Zoberi, MD¹, Thomas Mazur, PhD¹, Jiayi Huang, MD¹, Hiram Gay, MD¹, Vivian Rodriguez, PhD¹, Sasa Mutic, PhD¹, Jeff M Michalski, MD, MBA¹; ¹Washington University in St. Louis, ²University of Colorado

P098: A TREATMENT PLANNING COMPARISON BETWEEN NOVEL COBALT-60 WITH A RING TYPE GANTRY AND ROBOTIC LINEAR ACCELERATOR BASED STEREOTACTIC RADIOSURGERY / RADIOTHERAPY FOR BRAIN METASTASES - Muhammad M Fareed, Ahmed Eldib, Stephanie E Weiss, Shelly B Hayes, Charlie M Ma; Fox Chase Cancer Center

P099: LOW-DOSE RADIOTHERAPY IS AN EFFECTIVE TREATMENT FOR REFRACTORY POST-OPERATIVE CHYLOUS ASCITES: A CASE REPORT. - Si-mon Brown, Timur Mitin, MD, PhD, Charles Thomas, MD, Erin Gilbert, MD; Oregon Health and Science University

P100: BURNOUT AMONG TRAINEES IN RADIATION ONCOLOGY: DETERMINING THE ROOT OF THE PROBLEM - Awad A Ahmed, MD, Stephen J Ramey, MD, Cristiane Takita, MD, MBA, Raphael Yechieli, MD; University of Miami

P101: BURNOUT EVALUATION OF RADIATION RESIDENTS NATIONWIDE (BERRN): RESULTS OF A SURVEY OF UNITED STATES RESIDENTS - Ste-phen J Ramey, MD, Awad A Ahmed, MD, Bryan Jimenez, BS, Cristiane Takita, MD, MBA, Raphael Yechieli, MD; Department of Radiation Oncology, Univer-sity of Miami/Jackson Memorial Hospital

P102: SURVIVAL AFTER CHEMOTHERAPY AND STEM CELL TRANSPLANT FOLLOWED BY DELAYED CRANIOSPINAL IRRADIATION IS COMPARA-BLE TO UPFRONT CRANIOSPINAL IRRADIATION IN PEDIATRIC EMBRYONAL BRAIN TUMOR PATIENTS - David R Raleigh, MD, PhD¹, Bryan Tomlin, PhD², Benedict Del Buono¹, Erika Roddy¹, Katherine Sear¹, Lennox Byer¹, Erin Felton¹, Anu Banerjee, MD¹, Joseph Torkildson, MD³, David Samuel, MD⁴, Biljana Horn, MD¹, Steve E Braunstein, MD, PhD¹, Daphne A Haas-Kogan, MD⁵; ¹UCSF, ²California State University Channel Islands, ³UCSF Benioff Chil-dren’s Hospital Oakland, ⁴Valley Medical Oncology, ⁵Dana Farber Institute

P103: PREOPERATIVE VERSUS POSTOPERATIVE RADIOTHERAPY IN LOCALIZED SOFT TISSUE SARCOMA: NATIONWIDE PATTERNS OF CARE AND TRENDS IN UTILIZATION - Stanislav Lazarev, MD¹, Heather McGee, MD, PhD¹, Erin Moshier, MS², Meng Ru, MS², Elizabeth G Demicco, MD, PhD³, Vishal Gupta, MD¹; ¹Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, ²Department of Population Health Science & Policy, Icahn School of Medicine at Mount Sinai, ³Department of Pathology, Icahn School of Medicine at Mount Sinai

P104: RADIATION AND SUBSEQUENT REIRRADIATION OUTCOMES IN THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA AND A SYS-TEMATIC REVIEW OF THE REIRRADIATION LITERATURE - Chris Freese, MD¹, Vinita Takiar, MD, PhD¹, Maryam Fouladi, MD, MS², Ralph Vatner, MD, PhD¹, Mariko DeWire, MD², John Breneman, MD¹, Luke Pater, MD¹; ¹Departments of Radiation Oncology at the University of Cincinnati Barrett Cancer Center, ²Division of Oncology at the Cincinnati Children’s Hospital Medical Center

P105: CHARACTERIZATION AND PREDICTIVE VALUE OF VOLUME CHANGES OF EXTREMITY AND PELVIS SOFT-TISSUE SARCOMAS DURING RA-DIOTHERAPY PRIOR TO SURGICAL RESECTION - Chengcheng Gui, BSE, Carol D Morris, MD, MS, Christian F Meyer, MD, MS, PhD, Adam S Levin, MD, Deborah A Frassica, MD, Curtiland Deville, MD, Stephanie A Terezakis, MD; Johns Hopkins University School of Medicine

P106: THE GRAY HAS GOT TO GO! INADEQUACIES IN THE CURRENT UNITS OF ABSORBED DOSE - Chary Rangacharyulu, PhD¹, Christine K Roh¹, Ramy Tannous¹, James S Welsh, MS, MD²; ¹University of Saskatchewan, ²Loyola Stritch School of Medicine

P107: ANOMALOUS VARIATIONS IN NUCLEAR DECAY: POTENTIAL RADIATION ONCOLOGY IMPLICATIONS - James S Welsh¹, Ephraim Fischbach, PhD2; 1Loyola Stritch School of Medicine, 2Purdue University

P108: LOCAL CONTROL AND TOXICITY OF REIRRADIATION WITH PULSED LOW-DOSE-RATE RADIATION - Charles T Lee, Yanqun Dong, MD, PhD, Tianyu Li, MS, Samuel Freedman, Jordan Anaokar, MD, Thomas J Galloway, MD, Mark A Hallman, MD, PhD, Stephanie E Weiss, MD, Shelly B Hayes, MD, Robert A Price, PhD, Charlie Ma, PhD, Joshua E Meyer, MD; Fox Chase Cancer Center

P109: FACTORS ASSOCIATED WITH INCREASE IN FATIGUE IN PROSTATE CANCER (PC) PATIENTS UNDERGOING EXTERNAL BEAM RADIATION THERAPY (EBRT) - Hann-Hsiang Chao, MD, PhD, Abigail Doucette, MS, David M Raizen, MD, PhD, Neha Vapiwala, MD; University of Pennsylvania

P110: A MODIFIED EDMONTON SYMPTOM ASSESSMENT SCALE FOR SYMPTOM CLUSTERS IN RADIATION ONCOLOGY PATIENTS - Amber G Orman, MD, Zhenjun Ma, PhD, Jun-Min Zhou, PhD, Diane Portman, MD, Heather Jim, PhD, Peter Johnstone, MD, Michael Yu, MD; Moffitt Cancer Center & Research Institute

P111: LONG TERM VISUAL OUTCOMES FOR OCULAR MELANOMA PATIENTS TREATED WITH I-125 BRACHYTHERAPY EYE PLAQUES - Steven Engel, MD, Christopher Dermarkarian, BS, Arnold Markoe, MD, Mary Dean, MD, Raphael Yechieli, MD, William Harbour, MD; University of Miami

P112: DOES EARLY RADIATION ONCOLOGY INTERVENTION LEAD TO DECREASED HOSPITAL STAYS? - Taylor R Cushman, MS1, Shervin M Shirvani, MD2, Mohamed K Khan, MD2, Rachit Kumar, MD2; 1University of Arizona College of Medicine-Phoenix, 2Division of Radiation Oncology, Banner MD Ander-son Cancer Center

P113: IMPACT OF RADIOTHERAPY TECHNIQUE ON NORMAL TISSUE DOSE IN TREATMENT OF SPINAL VERTEBRAL METASTASES - Richard S Piet-ers, MD, Professor of Radiation Oncology Peds, I-LinEric Kuo, MA, Thomas J FitzGerald, MD, Professor Chair; University of Massachusetts Medical School

SAVE THE DATE!

American Radium Society

100th Annual MeetingMay 5-8, 2018

Loews Portofino Bay Hotel

at Universal Orlando

President: Ben Slotman, MD, PhDProgram Chair: Beth Beadle, MD, PhD

WHO SHOULD ATTEND?ARS members and non-members specializing or training in the field of Oncology including:

Radiation OncologySurgical Oncology

Gynecologic OncologyMedical Oncology

Head and Neck Oncology

Allied scientists, medical physicists and others interested in cancer

treatment

For general information visit www.americanradiumsociety.org

Thank you to our 2017 Supporters

The ARS would like to thank the following companies for providing educational grants in support of the

99th Annual Meeting:

PLATINUM LEVELVarian Medical Systems

SILVER LEVELElekta, Inc.

Hitachi America, Ltd.Mevion Medical Systems

BRONZE LEVELAstraZenecaViewRay, Inc.

SPONSORSHIP: RESIDENT JEOPARDYVarian Medical Systems

SPONSORSHIP: KEYNOTE LECTURE – DR. CRYSTAL L. MACKALLBayer